

# Giuseppe Remuzzi

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5360335/giuseppe-remuzzi-publications-by-citations.pdf>

**Version:** 2023-06-03

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

1,320  
papers

138,848  
citations

157  
h-index

345  
g-index

1,389  
ext. papers

158,418  
ext. citations

11  
avg, IF

8.73  
L-index

#	Paper	IF	Citations
1320	Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , <b>2012</b> , 380, 2095-128	36.2	8853
1319	Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , <b>2012</b> , 380, 2197-223	36.2	5769
1318	Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. <i>New England Journal of Medicine</i> , <b>2001</b> , 345, 861-9	57.2	5533
1317	Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , <b>2012</b> , 380, 2163-96	36.2	4924
1316	Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , <b>2015</b> , 385, 117-71	36.2	4601
1315	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , <b>2015</b> , 386, 743-800	36.2	3776
1314	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , <b>2016</b> , 388, 1459-1544	36.2	3503
1313	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , <b>2017</b> , 390, 1151-1210	36.2	2523
1312	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , <b>2016</b> , 388, 1659-1724	36.2	2401
1311	Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. <i>Lancet, The</i> , <b>2003</b> , 362, 1527-35	36.2	1998
1310	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , <b>2015</b> , 386, 2287-323	36.2	1782
1309	COVID-19 and Italy: what next?. <i>Lancet, The</i> , <b>2020</b> , 395, 1225-1228	36.2	1724
1308	A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 2019-32	57.2	1744
1307	von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. <i>New England Journal of Medicine</i> , <b>1998</b> , 339, 1578-84	57.2	1471
1306	Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 1395-407	57.2	1456
1305	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , <b>2016</b> , 388, 1603-1658	36.2	1227
1304	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. <i>Lancet, The</i> , <b>2015</b> , 386, 2145-91	36.2	1213

1303	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , <b>2017</b> , 390, 1260-1344	36.2	1152
1302	Pathophysiology of progressive nephropathies. <i>New England Journal of Medicine</i> , <b>1998</b> , 339, 1448-56	57.2	1017
1301	Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. <i>New England Journal of Medicine</i> , <b>2013</b> , 368, 2169-81	57.2	960
1300	Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , <b>2020</b> , 395, 709-733	36.2	979
1299	Atypical hemolytic-uremic syndrome. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 1676-87	57.2	926
1298	Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , <b>2012</b> , 380, 2129-43	36.2	835
1297	Preventing microalbuminuria in type 2 diabetes. <i>New England Journal of Medicine</i> , <b>2004</b> , 351, 1941-51	57.2	797
1296	The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. <i>Kidney International</i> , <b>2011</b> , 80, 1258-70	9.6	808
1295	Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. <i>Annals of Internal Medicine</i> , <b>2001</b> , 135, 73-87	7.8	723
1294	Delayed graft function in kidney transplantation. <i>Lancet, The</i> , <b>2004</b> , 364, 1814-27	36.2	695
1293	Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. <i>Kidney International</i> , <b>2004</b> , 65, 2309-20	9.6	682
1292	Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. <i>Lancet, The</i> , <b>1999</b> , 354, 359-64	36.2	680
1291	Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , <b>2014</b> , 384, 1005-70	36.2	649
1290	Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2010</b> , 5, 1844-59	6.7	642
1289	Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 2492-503	57.2	658
1288	Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2004</b> , 15, 1794-804	12.3	616
1287	Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. <i>Circulation</i> , <b>2004</b> , 110, 921-7	16.3	588
1286	Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. <i>Blood</i> , <b>2006</b> , 108, 1267-79	2.1	560

1285	How does proteinuria cause progressive renal damage?. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2006</b> , 17, 2974-84	12.3	540
1284	Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. <i>New England Journal of Medicine</i> , <b>1983</b> , 308, 8-12	57.2	536
1283	Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. <i>Lancet, The</i> , <b>2010</b> , 376, 1543-51	36.2	531
1282	Panethnic Differences in Blood Pressure in Europe: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , <b>2016</b> , 11, e0147601	3.6	511
1281	International Society of Nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. <i>Lancet, The</i> , <b>2015</b> , 385, 2616-43	36.2	527
1280	Global, regional, and national levels of maternal mortality, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , <b>2016</b> , 388, 1775-1812	36.2	478
1279	Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. <i>Kidney International</i> , <b>2011</b> , 79, 1331-40	9.6	468
1278	Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. <i>Lancet, The</i> , <b>2005</b> , 365, 939-46	36.2	483
1277	Understanding the nature of renal disease progression. <i>Kidney International</i> , <b>1997</b> , 51, 2-15	9.6	463
1276	Clinical practice. Nephropathy in patients with type 2 diabetes. <i>New England Journal of Medicine</i> , <b>2002</b> , 346, 1145-51	57.2	449
1275	Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. <i>Lancet, The</i> , <b>1998</b> , 352, 1252-6	36.2	459
1274	Angiotensin II revisited: new roles in inflammation, immunology and aging. <i>EMBO Molecular Medicine</i> , <b>2010</b> , 2, 247-57	11.6	432
1273	Progression, remission, regression of chronic renal diseases. <i>Lancet, The</i> , <b>2001</b> , 357, 1601-8	36.2	429
1272	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , <b>2017</b> , 390, 1084-1150	36.2	416
1271	Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. <i>Journal of Clinical Investigation</i> , <b>2006</b> , 116, 288-96	15.3	416
1270	Thrombomodulin mutations in atypical hemolytic-uremic syndrome. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 345-57	57.2	413
1269	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , <b>2016</b> , 388, 1725-1774	36.2	412
1268	Overview of complement activation and regulation. <i>Seminars in Nephrology</i> , <b>2013</b> , 33, 479-92	4.6	401

1267	Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. <i>Lancet, The</i> , <b>2017</b> , 390, 1888-1917	36.2	415
1266	Hemolytic uremic syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2005</b> , 16, 1035-50	12.3	390
1265	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. <i>Lancet HIV,the</i> , <b>2016</b> , 3, e361-e387	7.6	380
1264	Disruption of the Ang II type 1 receptor promotes longevity in mice. <i>Journal of Clinical Investigation</i> , <b>2009</b> , 119, 524-30	15.3	371
1263	Long-term outcome of renal transplantation from older donors. <i>New England Journal of Medicine</i> , <b>2006</b> , 354, 343-52	57.2	372
1262	Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. <i>Journal of Immunology</i> , <b>2008</b> , 181, 3933-46	5.2	368
1261	Nitric oxide synthesis by cultured endothelial cells is modulated by flow conditions. <i>Circulation Research</i> , <b>1995</b> , 76, 536-43	15.3	363
1260	Global and National Burden of Diseases and Injuries Among Children and Adolescents Between 1990 and 2013: Findings From the Global Burden of Disease 2013 Study. <i>JAMA Pediatrics</i> , <b>2016</b> , 170, 267-87	8	346
1259	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: a novel analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , <b>2017</b> , 390, 231-266	36.2	350
1258	Erythropoietic response and outcomes in kidney disease and type 2 diabetes. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 1146-55	57.2	344
1257	Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 314, 884-94	26.8	337
1256	Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. <i>Stem Cells</i> , <b>2008</b> , 26, 2075-82	5.5	325
1255	Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. <i>Kidney International</i> , <b>1998</b> , 53, 1608-15	9.6	324
1254	Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. <i>Kidney International</i> , <b>2001</b> , 60, 831-46	9.6	316
1253	Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. <i>Journal of Clinical Investigation</i> , <b>1998</b> , 101, 1905-15	15.3	315
1252	Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. <i>Kidney International</i> , <b>2006</b> , 69, 2057-63	9.6	316
1251	Platelet dysfunction in renal failure. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2004</b> , 30, 579-89	5.1	308
1250	Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). <i>Kidney International</i> , <b>1998</b> , 53, 1209-16	9.6	303

1249	The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. <i>Kidney International</i> , <b>2005</b> , S57-65	9.6	300
1248	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , <b>2016</b> , 388, 1813-1850	36.2	305
1247	Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy-induced hypertension. <i>New England Journal of Medicine</i> , <b>1989</b> , 321, 357-62	57.2	292
1246	Prognosis of untreated patients with idiopathic membranous nephropathy. <i>New England Journal of Medicine</i> , <b>1993</b> , 329, 85-9	57.2	282
1245	STEC-HUS, atypical HUS and TTP are all diseases of complement activation. <i>Nature Reviews Nephrology</i> , <b>2012</b> , 8, 622-33	14.3	275
1244	Familial haemolytic uraemic syndrome and an MCP mutation. <i>Lancet, The</i> , <b>2003</b> , 362, 1542-7	36.2	269
1243	Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. <i>Kidney International</i> , <b>2001</b> , 60, 1131-40	9.6	267
1242	Early experience with dual kidney transplantation in adults using expanded donor criteria. Double Kidney Transplant Group (DKG). <i>Journal of the American Society of Nephrology: JASN</i> , <b>1999</b> , 10, 2591-8	12.3	241
1241	Plasma clearance of nonradioactive iothexol as a measure of glomerular filtration rate. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1995</b> , 6, 257-63	12.3	251
1240	Insulin-like growth factor-1 sustains stem cell mediated renal repair. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2007</b> , 18, 2921-8	12.3	263
1239	Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. <i>Human Molecular Genetics</i> , <b>2003</b> , 12, 3385-95	5.5	260
1238	Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. <i>Kidney International</i> , <b>2015</b> , 87, 1061-73	9.6	255
1237	Transfer of growth factor receptor mRNA via exosomes unravels the regenerative effect of mesenchymal stem cells. <i>Stem Cells and Development</i> , <b>2013</b> , 22, 772-80	4.2	257
1236	Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. <i>Journal of Clinical Investigation</i> , <b>2003</b> , 111, 1181-90	15.3	254
1235	Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2013</b> , 24, 475-86	12.3	252
1234	Chronic kidney disease. <i>Nature Reviews Disease Primers</i> , <b>2017</b> , 3, 17088	49	249
1233	Podocyte number in normotensive type 1 diabetic patients with albuminuria. <i>Diabetes</i> , <b>2002</b> , 51, 3083-9	0.7	247
1232	Transplant renal artery stenosis. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2004</b> , 15, 134-41	12.3	239

1231	Uraemic bleeding: role of anaemia and beneficial effect of red cell transfusions. <i>Lancet, The</i> , <b>1982</b> , 2, 1013-5	36.2	241
1230	Sirtuin 3-dependent mitochondrial dynamic improvements protect against acute kidney injury. <i>Journal of Clinical Investigation</i> , <b>2015</b> , 125, 715-26	15.3	240
1229	MicroRNAs in kidney physiology and disease. <i>Nature Reviews Nephrology</i> , <b>2015</b> , 11, 23-33	14.3	239
1228	Strategies for making more organs available for transplantation. <i>New England Journal of Medicine</i> , <b>2000</b> , 343, 404-10	57.2	238
1227	Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. <i>Blood</i> , <b>2005</b> , 106, 1932-7	2.1	235
1226	Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. <i>Kidney International</i> , <b>2005</b> , S7-S10	9.6	225
1225	Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2011</b> , 6, 412-22	6.7	228
1224	ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. <i>Blood</i> , <b>2005</b> , 106, 1262-7	2.1	228
1223	Haemolytic-uraemic syndrome: deficiency of plasma factor(s) regulating prostacyclin activity?. <i>Lancet, The</i> , <b>1978</b> , 2, 871-2	36.2	230
1222	Rituximab for idiopathic membranous nephropathy. <i>Lancet, The</i> , <b>2002</b> , 360, 923-4	36.2	229
1221	Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2007</b> , 18, 1540-6	12.3	239
1220	The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2001</b> , 12, 297-307	12.3	204
1219	Endothelin antagonists. <i>Lancet, The</i> , <b>1999</b> , 353, 133-8	36.2	226
1218	Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. <i>Blood</i> , <b>2014</b> , 124, 1715-26	2.1	219
1217	Sodium intake, ACE inhibition, and progression to ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2012</b> , 23, 165-73	12.3	224
1216	Mechanisms of disease: Pre-eclampsia. <i>Nature Clinical Practice Nephrology</i> , <b>2005</b> , 1, 98-114; quiz 120		212
1215	Factor H family proteins: on complement, microbes and human diseases. <i>Biochemical Society Transactions</i> , <b>2002</b> , 30, 971-8	5	215
1214	Recognition and management of acute kidney injury in the International Society of Nephrology Oby25 Global Snapshot: a multinational cross-sectional study. <i>Lancet, The</i> , <b>2016</b> , 387, 2017-25	36.2	218

1213	Child and Adolescent Health From 1990 to 2015: Findings From the Global Burden of Diseases, Injuries, and Risk Factors 2015 Study. <i>JAMA Pediatrics</i> , <b>2017</b> , 171, 573-592	8	215
1212	Reduced umbilical and placental vascular prostacyclin in severe pre-eclampsia. <i>Prostaglandins</i> , <b>1980</b> , 20, 105-10		211
1211	Glomerular hyperfiltration and renal disease progression in type 2 diabetes. <i>Diabetes Care</i> , <b>2012</b> , 35, 2061-8	14.1	213
1210	Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. <i>American Journal of Kidney Diseases</i> , <b>1995</b> , 26, 934-41	7.2	214
1209	Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 318, 432-442	26.8	218
1208	A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. <i>Kidney International</i> , <b>2006</b> , 70, 423-31	9.6	202
1207	Regulatory T cells and T cell depletion: role of immunosuppressive drugs. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2007</b> , 18, 1007-18	12.3	203
1206	MYO1E mutations and childhood familial focal segmental glomerulosclerosis. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 295-306	57.2	196
1205	The RAAS in the pathogenesis and treatment of diabetic nephropathy. <i>Nature Reviews Nephrology</i> , <b>2010</b> , 6, 319-30	14.3	193
1204	Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. <i>Nature Reviews Nephrology</i> , <b>2021</b> , 17, 46-64	14.3	195
1203	Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. <i>Annals of Internal Medicine</i> , <b>2002</b> , 136, 604-15	7.8	192
1202	Conjugated estrogens for the management of bleeding associated with renal failure. <i>New England Journal of Medicine</i> , <b>1986</b> , 315, 731-5	57.2	188
1201	Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. <i>The Lancet Global Health</i> , <b>2016</b> , 4, e307-19	12	206
1200	Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. <i>Kidney International</i> , <b>2005</b> , 68, 206-16	9.6	192
1199	Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. <i>Journal of Immunology</i> , <b>2011</b> , 187, 172-80	5.2	187
1198	Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. <i>Kidney International</i> , <b>2003</b> , 63, 2254-61	9.6	184
1197	In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1998</b> , 9, 1213-24	12.3	182
1196	Rituximab in idiopathic membranous nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2012</b> , 23, 1416-25	12.3	185



1195	A phase 1, single-dose study of fresolimumab, an anti-TGF- $\beta$ antibody, in treatment-resistant primary focal segmental glomerulosclerosis. <i>Kidney International</i> , <b>2011</b> , 79, 1236-43	9.6	182
1194	von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. <i>Blood</i> , <b>2002</b> , 100, 778-85	2.1	184
1193	Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2015</b> , 26, 2545-58	12.3	187
1192	HUS and TTP: variable expression of a single entity. <i>Kidney International</i> , <b>1987</b> , 32, 292-308	9.6	182
1191	Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. <i>Lancet, The</i> , <b>2013</b> , 382, 1485-95	36.2	181
1190	Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade. <i>Nephron</i> , <b>2020</b> , 144, 213-221	3.1	178
1189	A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. <i>Kidney International</i> , <b>1993</b> , 44, 440-4	9.6	177
1188	Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. <i>Kidney International</i> , <b>2002</b> , 62, 1060-7	9.6	180
1187	Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions?. <i>Circulation</i> , <b>1999</b> , 100, 55-60	16.3	178
1186	Tumor necrosis factor induces glomerular damage in the rabbit. <i>American Journal of Pathology</i> , <b>1989</b> , 134, 419-30	5.6	177
1185	Mechanisms and treatment of CKD. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2012</b> , 23, 1917-28.3	28.3	179
1184	The case of complement activation in COVID-19 multiorgan impact. <i>Kidney International</i> , <b>2020</b> , 98, 314-322	32.2	177
1183	Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. <i>Journal of Clinical Investigation</i> , <b>1990</b> , 85, 541-9	15.3	173
1182	Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2015</b> , 26, 1732-46	12.3	178
1181	Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes. <i>BMJ: British Medical Journal</i> , <b>1998</b> , 316, 504-9		175
1180	Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2015</b> , 10, 592-600	6.7	175
1179	Heterogeneous nature of renal lesions in type II diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1993</b> , 3, 1458-66	12.3	160
1178	Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2006</b> , 1, 88-99	6.7	175

1177	Performance of different prediction equations for estimating renal function in kidney transplantation. <i>American Journal of Transplantation</i> , <b>2004</b> , 4, 1826-35	8.4	172
1176	Rituximab in idiopathic membranous nephropathy: a one-year prospective study. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2003</b> , 14, 1851-7	12.3	170
1175	Nonviral gene delivery to the rat kidney with polyethylenimine. <i>Human Gene Therapy</i> , <b>1997</b> , 8, 1243-51	4.7	167
1174	Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2011</b> , 22, 1923-30	12.3	174
1173	Fluid shear stress modulates surface expression of adhesion molecules by endothelial cells. <i>Blood</i> , <b>1995</b> , 85, 1696-1703	2.1	166
1172	The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2014</b> , 25, 1083-93	12.3	168
1171	Renal vascular and thrombotic effects of cyclosporine. <i>American Journal of Kidney Diseases</i> , <b>1989</b> , 13, 261-72	7.2	165
1170	Thrombotic microangiopathy after kidney transplantation. <i>American Journal of Transplantation</i> , <b>2010</b> , 10, 1517-23	8.4	156
1169	Time to abandon microalbuminuria?. <i>Kidney International</i> , <b>2006</b> , 70, 1214-22	9.6	158
1168	Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2003</b> , 14, 1816-24	12.3	162
1167	The hemolytic uremic syndrome. <i>Kidney International</i> , <b>1995</b> , 48, 2-19	9.6	162
1166	Role of remission clinics in the longitudinal treatment of CKD. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2008</b> , 19, 1213-24	12.3	165
1165	Uremic Bleeding: Closing the Circle After 30 Years of Controversies?. <i>Blood</i> , <b>1999</b> , 94, 2569-2574	2.1	158
1164	Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus. <i>Journal of Clinical Investigation</i> , <b>1985</b> , 76, 1011-8	15.3	156
1163	Hepatitis C infection and chronic renal diseases. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2009</b> , 4, 207-20	6.7	149
1162	Life-sparing effect of human cord blood-mesenchymal stem cells in experimental acute kidney injury. <i>Stem Cells</i> , <b>2010</b> , 28, 513-22	5.5	143
1161	ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2001</b> , 12, 2832-2837	12.3	141
1160	Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. <i>American Journal of Kidney Diseases</i> , <b>2000</b> , 35, 1155-65	7.2	149

1159	Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. <i>Kidney International</i> , <b>1993</b> , 43, 706-11	9.6	146
1158	Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2014</b> , 25, 850-63	12.3	145
1157	Renal progenitor cells contribute to hyperplastic lesions of podocytopathies and crescentic glomerulonephritis. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2009</b> , 20, 2593-603	12.3	145
1156	Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1993</b> , 4, 40-9	12.3	137
1155	Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2006</b> , 17, S90-7	12.3	140
1154	Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension. <i>Kidney International</i> , <b>1993</b> , 44, 445-50	9.6	141
1153	The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models. <i>Human Mutation</i> , <b>2007</b> , 28, 222-34	4.6	141
1152	Insulin resistance and microalbuminuria: a cross-sectional, case-control study of 158 patients with type 2 diabetes and different degrees of urinary albumin excretion. <i>Diabetes</i> , <b>2006</b> , 55, 1456-62	0.7	140
1151	Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. <i>Kidney International</i> , <b>2003</b> , 63, 1094-103	9.6	137
1150	Early-childhood membranous nephropathy due to cationic bovine serum albumin. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 2101-10	57.2	142
1149	Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. <i>Lancet, The</i> , <b>2002</b> , 359, 1671-2	36.2	140
1148	Bleeding in renal failure. <i>Lancet, The</i> , <b>1988</b> , 1, 1205-8	36.2	140
1147	Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2009</b> , 20, 940-9	12.3	142
1146	Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. <i>Lancet, The</i> , <b>2004</b> , 364, 503-12	36.2	134
1145	Renal progenitors: an evolutionary conserved strategy for kidney regeneration. <i>Nature Reviews Nephrology</i> , <b>2013</b> , 9, 137-46	14.3	133
1144	Protein overload-induced NF-kappaB activation in proximal tubular cells requires H <sub>2</sub> O <sub>2</sub> through a PKC-dependent pathway. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2002</b> , 13, 1179-89	12.3	133
1143	Recellularization of well-preserved acellular kidney scaffold using embryonic stem cells. <i>Tissue Engineering - Part A</i> , <b>2014</b> , 20, 1486-98	3.7	132
1142	Rare inherited kidney diseases: challenges, opportunities, and perspectives. <i>Lancet, The</i> , <b>2014</b> , 383, 1844-52	35.9	133

1141	Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2006</b> , 1, 761-7	6.7	136
1140	Protein traffic activates NF- $\kappa$ B gene signaling and promotes MCP-1-dependent interstitial inflammation. <i>American Journal of Kidney Diseases</i> , <b>2000</b> , 36, 1226-41	7.2	133
1139	Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation. <i>Transplantation</i> , <b>1992</b> , 54, 56-60	1.5	130
1138	Increased glomerular thromboxane synthesis as a possible cause of proteinuria in experimental nephrosis. <i>Journal of Clinical Investigation</i> , <b>1985</b> , 75, 94-101	15.3	132
1137	In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies. <i>American Journal of Pathology</i> , <b>2005</b> , 166, 1309-20	5.6	130
1136	Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy. <i>Kidney International</i> , <b>1986</b> , 30, 488-96	9.6	133
1135	How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2002</b> , 13, 2898-908	12.3	137
1134	Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. <i>Transplant International</i> , <b>2013</b> , 26, 867-78	2.9	128
1133	Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry. <i>Nephrology Dialysis Transplantation</i> , <b>2014</b> , 29 Suppl 4, iv15-25	4.1	124
1132	In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1999</b> , 10, 997-1006	12.3	124
1131	Sirolimus therapy to halt the progression of ADPKD. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2010</b> , 21, 1031-40	12.3	128
1130	Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. <i>Transplantation</i> , <b>2000</b> , 69, 827-33	1.5	124
1129	Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation. <i>American Journal of Transplantation</i> , <b>2012</b> , 12, 2373-83	8.4	125
1128	In vivo maturation of functional renal organoids formed from embryonic cell suspensions. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2012</b> , 23, 1857-68	12.3	125
1127	Global Cardiovascular and Renal Outcomes of Reduced GFR. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2017</b> , 28, 2167-2179	12.3	130
1126	Maintenance Dialysis throughout the World in Years 1990 and 2010. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2015</b> , 26, 2621-33	12.3	128
1125	L-arginine depletion in preeclampsia orients nitric oxide synthase toward oxidant species. <i>Hypertension</i> , <b>2004</b> , 43, 614-22	8	122
1124	Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2007</b> , 18, 1959-65	12.3	123

1123	Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. <i>Kidney International</i> , <b>1993</b> , 43, 354-8	9.6	118
1122	Reduced platelet thromboxane formation in uremia. Evidence for a functional cyclooxygenase defect. <i>Journal of Clinical Investigation</i> , <b>1983</b> , 71, 762-8	15.3	121
1121	Eculizumab in a patient with dense-deposit disease. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 1161-3	57.2	117
1120	Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome. <i>Transplantation</i> , <b>2002</b> , 74, 1095-102	1.5	114
1119	Cellular responses to protein overload: key event in renal disease progression. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2004</b> , 13, 31-7	3.4	118
1118	Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2005</b> , 16, 1177-83	12.3	115
1117	Pathophysiologic implications of reduced podocyte number in a rat model of progressive glomerular injury. <i>American Journal of Pathology</i> , <b>2006</b> , 168, 42-54	5.6	115
1116	Transforming growth factor-beta1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis. <i>American Journal of Pathology</i> , <b>2002</b> , 161, 2179-93	5.6	118
1115	Kidney graft survival in rats without immunosuppressants after intrathymic glomerular transplantation. <i>Lancet, The</i> , <b>1991</b> , 337, 750-2	36.2	115
1114	Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. <i>Kidney International</i> , <b>1997</b> , 51, 1583-9	9.6	120
1113	Thymic recognition of class II major histocompatibility complex allopeptides induces donor-specific unresponsiveness to renal allografts. <i>Transplantation</i> , <b>1993</b> , 56, 461-5	1.5	117
1112	Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. <i>Lancet Diabetes and Endocrinology,the</i> , <b>2019</b> , 7, 128-139	17.4	118
1111	Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. <i>Molecular Immunology</i> , <b>2008</b> , 45, 95-105	4.2	113
1110	Bone marrow-derived mesenchymal stem cells improve islet graft function in diabetic rats. <i>Transplantation Proceedings</i> , <b>2009</b> , 41, 1797-800	1.1	113
1109	Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1999</b> , 10, 281-93	12.3	106
1108	New therapeutics that antagonize endothelin: promises and frustrations. <i>Nature Reviews Drug Discovery</i> , <b>2002</b> , 1, 986-1001	62	115
1107	Kidney regeneration. <i>Lancet, The</i> , <b>2010</b> , 375, 1310-7	36.2	112
1106	Renal and systemic nitric oxide synthesis in rats with renal mass reduction. <i>Kidney International</i> , <b>1997</b> , 52, 171-81	9.6	111

1105	Podocyte-actin dynamics in health and disease. <i>Nature Reviews Nephrology</i> , <b>2016</b> , 12, 692-710	14.3	110
1104	Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. <i>Lancet Diabetes and Endocrinology</i> , <b>2019</b> , 7, 115-127	17.4	108
1103	Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation. <i>American Journal of Transplantation</i> , <b>2005</b> , 5, 1146-50	8.4	112
1102	Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases. <i>Annals of Internal Medicine</i> , <b>1999</b> , 130, 422-6	7.8	108
1101	Plasma infusion for hemolytic-uremic syndrome in children: results of a multicenter controlled trial. <i>Journal of Pediatrics</i> , <b>1988</b> , 112, 284-90	3.5	110
1100	The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. <i>Kidney International</i> , <b>2013</b> , 84, 164-73	9.6	113
1099	Fluid Shear Stress Modulates von Willebrand Factor Release From Human Vascular Endothelium. <i>Blood</i> , <b>1997</b> , 90, 1558-1564	2.1	108
1098	Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2007</b> , 2, 932-7	6.7	107
1097	Role of insulin and atrial natriuretic peptide in sodium retention in insulin-treated IDDM patients during isotonic volume expansion. <i>Diabetes</i> , <b>1990</b> , 39, 289-98	0.7	107
1096	Interleukin-1 beta and tumor necrosis factor-alpha induce gene expression and production of leukocyte chemotactic factors, colony-stimulating factors, and interleukin-6 in human mesangial cells. <i>American Journal of Pathology</i> , <b>1991</b> , 138, 991-1003	5.6	108
1095	Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. <i>Kidney International</i> , <b>2005</b> , 67, 1753-61	9.6	106
1094	Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1999</b> , 10, 1542-9	12.3	108
1093	Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. <i>Molecular Immunology</i> , <b>2007</b> , 44, 111-22	4.2	106
1092	Protein overload induces fractalkine upregulation in proximal tubular cells through nuclear factor kappaB- and p38 mitogen-activated protein kinase-dependent pathways. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2003</b> , 14, 2436-46	12.3	108
1091	Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events. <i>Laboratory Investigation</i> , <b>1982</b> , 46, 16-23	5.7	105
1090	C3 glomerulopathy - understanding a rare complement-driven renal disease. <i>Nature Reviews Nephrology</i> , <b>2019</b> , 15, 129-143	14.3	104
1089	Human amniotic fluid stem cell preconditioning improves their regenerative potential. <i>Stem Cells and Development</i> , <b>2012</b> , 21, 1911-23	4.2	103
1088	Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2010</b> , 5, 783-9	6.7	105

1087	The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , <b>2000</b> , 1, 328-35	2.9	103
1086	Blocking angiotensin II synthesis/activity preserves glomerular nephrin in rats with severe nephrosis. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2001</b> , 12, 941-948	12.3	100
1085	Precision of plasma clearance of iohexol for estimation of GFR in patients with renal disease. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1998</b> , 9, 310-3	12.3	99
1084	Proteinuria should be used as a surrogate in CKD. <i>Nature Reviews Nephrology</i> , <b>2012</b> , 8, 301-6	14.3	101
1083	Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. <i>Journal of Hypertension</i> , <b>2007</b> , 25, 1921-6	1.5	103
1082	Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. <i>Diabetes</i> , <b>1998</b> , 47, 450-6	0.7	101
1081	Sex related differences in glomerular ultrafiltration and proteinuria in Munich-Wistar rats. <i>Kidney International</i> , <b>1988</b> , 34, 481-6	9.6	103
1080	Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015. <i>American Journal of Kidney Diseases</i> , <b>2015</b> , 66, 359-75	7.2	102
1079	Hemolytic Uremic Syndrome in Pregnancy and Postpartum. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2017</b> , 12, 1237-1247	6.7	100
1078	Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site. <i>American Journal of Pathology</i> , <b>2005</b> , 167, 1173-81	5.6	100
1077	The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis. <i>Nephrology Dialysis Transplantation</i> , <b>2003</b> , 18, 2047-53	4.1	102
1076	Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy. <i>Kidney International</i> , <b>2004</b> , 65, 2193-200	9.6	99
1075	Bleeding in renal failure: altered platelet function in chronic uraemia only partially corrected by haemodialysis. <i>Nephron</i> , <b>1978</b> , 22, 347-53	3.1	99
1074	Mesenchymal stromal cells in renal transplantation: opportunities and challenges. <i>Nature Reviews Nephrology</i> , <b>2016</b> , 12, 241-53	14.3	101
1073	Multipotent mesenchymal stromal cell therapy and risk of malignancies. <i>Stem Cell Reviews and Reports</i> , <b>2013</b> , 9, 65-79	6.1	100
1072	Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. <i>European Heart Journal</i> , <b>2011</b> , 32, 1493-9	9	98
1071	Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation. <i>American Journal of Transplantation</i> , <b>2006</b> , 6, 1948-52	8.4	103
1070	Endothelins in the control of cardiovascular and renal function. <i>Lancet, The</i> , <b>1993</b> , 342, 589-93	36.2	99

1069	Proximal tubular cells promote fibrogenesis by TGF-beta1-mediated induction of peritubular myofibroblasts. <i>Kidney International</i> , <b>2002</b> , 61, 2066-77	9.6	97
1068	Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. <i>Kidney International</i> , <b>1991</b> , 39, 1267-73	9.6	98
1067	Endothelin mediates the renal vasoconstriction induced by cyclosporine in the rat. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1990</b> , 1, 76-83	12.3	99
1066	Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. <i>American Journal of Physiology - Renal Physiology</i> , <b>2009</b> , 297, F1448-56	4.1	99
1065	Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1998</b> , 9, 1948-55	12.3	94
1064	Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. <i>American Heart Journal</i> , <b>2005</b> , 149, 408-13	4.7	100
1063	Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients. <i>Kidney International</i> , <b>1991</b> , 40, 243-50	9.6	98
1062	Adriamycin-induced glomerulosclerosis in the rat. <i>American Journal of Kidney Diseases</i> , <b>1986</b> , 7, 12-9	7.2	97
1061	Prostacyclin and human foetal circulation. <i>Prostaglandins</i> , <b>1979</b> , 18, 341-8		96
1060	The Nrf2 pathway in the progression of renal disease. <i>Nephrology Dialysis Transplantation</i> , <b>2014</b> , 29 Suppl 1, i19-i24	4.1	94
1059	Mutations in FN1 cause glomerulopathy with fibronectin deposits. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 2538-43	11.1	96
1058	MECHANISMS OF ACQUIRED THYMIC UNRESPONSIVENESS TO RENAL ALLOGRAFTS. <i>Transplantation</i> , <b>1994</b> , 58, 125-132	1.5	95
1057	Hemolytic uremic syndrome. <i>Seminars in Immunopathology</i> , <b>2014</b> , 36, 399-420	11.7	96
1056	Treatment of bleeding in dialysis patients. <i>Seminars in Dialysis</i> , <b>2009</b> , 22, 279-86	2.4	92
1055	Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). <i>Journal of the American Society of Nephrology: JASN</i> , <b>1998</b> , 9, 2096-101	12.3	91
1054	Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1. <i>Kidney International</i> , <b>2002</b> , 62, 846-56	9.6	93
1053	Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 1: How to measure glomerular filtration rate with iohexol?. <i>CKJ: Clinical Kidney Journal</i> , <b>2016</b> , 9, 682-99	4.4	97
1052	A novel strategy to enhance mesenchymal stem cell migration capacity and promote tissue repair in an injury specific fashion. <i>Cell Transplantation</i> , <b>2013</b> , 22, 423-36	3.8	93



1051	Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. <i>Blood</i> , <b>2012</b> , 120, 440-8	2.1	91
1050	Platelet hyperaggregability and the nephrotic syndrome. <i>Thrombosis Research</i> , <b>1979</b> , 16, 345-54	7.3	91
1049	Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. <i>Blood</i> , <b>2012</b> , 119, 3269-75	2.1	91
1048	Effect of angiotensin-converting enzyme inhibition on glomerular basement membrane permeability and distribution of zonula occludens-1 in MWF rats. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2000</b> , 11, 477-489	12.3	85
1047	Challenges to achieving clinical transplantation tolerance. <i>Journal of Clinical Investigation</i> , <b>2001</b> , 108, 943-948	15.3	91
1046	Inhibiting angiotensin-converting enzyme promotes renal repair by limiting progenitor cell proliferation and restoring the glomerular architecture. <i>American Journal of Pathology</i> , <b>2011</b> , 179, 628-38	5.6	91
1045	Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2004</b> , 15, 3117-25	12.3	90
1044	Effect of combining ACE inhibitor and statin in severe experimental nephropathy. <i>Kidney International</i> , <b>2002</b> , 61, 1635-45	9.6	90
1043	Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney. <i>American Journal of Kidney Diseases</i> , <b>1996</b> , 27, 416-23	7.2	88
1042	Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. <i>Journal of Immunology</i> , <b>2018</b> , 200, 2464-2478	5.2	88
1041	Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: effects of acetyl-L-carnitine therapy. <i>Hypertension</i> , <b>2009</b> , 54, 567-74	8	86
1040	Drug-induced thrombotic microangiopathy: incidence, prevention and management. <i>Drug Safety</i> , <b>2001</b> , 24, 491-501	5	86
1039	The aggravating mechanisms of aldosterone on kidney fibrosis. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2008</b> , 19, 1459-62	12.3	88
1038	ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. <i>Kidney International</i> , <b>2006</b> , 69, 1124-30	9.6	86
1037	Estimated GFR: time for a critical appraisal. <i>Nature Reviews Nephrology</i> , <b>2019</b> , 15, 177-190	14.3	85
1036	Podocyte repopulation contributes to regression of glomerular injury induced by ACE inhibition. <i>American Journal of Pathology</i> , <b>2009</b> , 174, 797-807	5.6	85
1035	Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2007</b> , 18, 1973-85	12.3	85
1034	Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling. <i>American Journal of Pathology</i> , <b>2006</b> , 169, 1965-75	5.6	84

1033	Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trial. <i>Lancet, The</i> , <b>2002</b> , 359, 663-6	36.2	86
1032	Monogenic diseases that can be cured by liver transplantation. <i>Journal of Hepatology</i> , <b>2013</b> , 59, 595-612	3.1	87
1031	ACE inhibition is renoprotective among obese patients with proteinuria. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2011</b> , 22, 1122-8	12.3	99
1030	Long-Term Outcome of Steroid-Resistant Nephrotic Syndrome in Children. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2017</b> , 28, 3055-3065	12.3	85
1029	Human mesenchymal stromal cells transplanted into mice stimulate renal tubular cells and enhance mitochondrial function. <i>Nature Communications</i> , <b>2017</b> , 8, 983	16.9	86
1028	Antiproteinuric therapy while preventing the abnormal protein traffic in proximal tubule abrogates protein- and complement-dependent interstitial inflammation in experimental renal disease. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1999</b> , 10, 804-13	12.3	83
1027	The nephropathy of non-insulin-dependent diabetes: predictors of outcome relative to diverse patterns of renal injury. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1998</b> , 9, 2336-43	12.3	75
1026	Verotoxin-1 promotes leukocyte adhesion to cultured endothelial cells under physiologic flow conditions. <i>Blood</i> , <b>1995</b> , 86, 4553-4558	2.1	84
1025	Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. <i>Lancet Diabetes and Endocrinology, the</i> , <b>2015</b> , 3, 181-90	17.4	85
1024	Disparities in Chronic Kidney Disease Prevalence among Males and Females in 195 Countries: Analysis of the Global Burden of Disease 2016 Study. <i>Nephron</i> , <b>2018</b> , 139, 313-318	3.1	88
1023	Progressive glomerular injury in the MWF rat is predicted by inborn nephron deficit. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1998</b> , 9, 1399-406	12.3	76
1022	Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. <i>Transplantation</i> , <b>2007</b> , 84, 956-64	1.5	85
1021	Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. <i>Molecular Immunology</i> , <b>2016</b> , 71, 131-142	4.2	83
1020	Translating the basic knowledge of mitochondrial functions to metabolic therapy: role of L-carnitine. <i>Translational Research</i> , <b>2013</b> , 161, 73-84	10.5	80
1019	Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1996</b> , 7, 653-60	12.3	76
1018	C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. <i>Pharmacogenomics</i> , <b>2007</b> , 8, 1127-41	2.5	82
1017	Role of endothelium-derived nitric oxide in the bleeding tendency of uremia. <i>Journal of Clinical Investigation</i> , <b>1990</b> , 86, 1768-71	15.3	81
1016	Verotoxin-1-induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. <i>Blood</i> , <b>2001</b> , 98, 1828-35	2.1	80

1015	Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year. <i>Kidney International</i> , <b>1999</b> , 55, 674-85	9.6	81
1014	Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: a multicenter randomised controlled clinical trial. <i>BMJ Open</i> , <b>2014</b> , 4, e003536	2.9	77
1013	A developmental approach to the prevention of hypertension and kidney disease: a report from the Low Birth Weight and Nephron Number Working Group. <i>Lancet, The</i> , <b>2017</b> , 390, 424-428	36.2	83
1012	Renal Dysfunction in the Presence of Normoalbuminuria in Type 2 Diabetes: Results from the DEMAND Study. <i>CardioRenal Medicine</i> , <b>2012</b> , 2, 1-10	2.7	80
1011	Risk of nonmelanoma skin cancer in Italian organ transplant recipients. A registry-based study. <i>Transplantation</i> , <b>2000</b> , 70, 1479-84	1.5	79
1010	Recent progress in the pathophysiology and treatment of FSGS recurrence. <i>American Journal of Transplantation</i> , <b>2013</b> , 13, 266-74	8.4	77
1009	The pathophysiology and management of thrombotic thrombocytopenic purpura. <i>European Journal of Haematology</i> , <b>1996</b> , 56, 191-207	3.6	78
1008	Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition. <i>Journal of Clinical Investigation</i> , <b>1987</b> , 79, 1788-97	15.3	78
1007	Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. <i>Journal of Hypertension</i> , <b>2006</b> , 24, 403-8	1.5	72
1006	Immunosuppressive treatment for idiopathic membranous nephropathy: A systematic review. <i>American Journal of Kidney Diseases</i> , <b>2004</b> , 44, 385-401	7.2	80
1005	Reversible activation defect of the platelet glycoprotein IIb-IIIa complex in patients with uremia. <i>American Journal of Kidney Diseases</i> , <b>1993</b> , 22, 668-76	7.2	77
1004	Analogues of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. <i>American Journal of Physiology - Renal Physiology</i> , <b>2013</b> , 304, F808-19	4.1	78
1003	Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. <i>Lancet, The</i> , <b>2021</b> , 397, 1625-1636	36.2	80
1002	Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL. <i>Kidney International</i> , <b>2006</b> , 69, 1675-82	9.6	75
1001	Effect of Cyclosporin A on prostacyclin synthesis by vascular tissue. <i>Thrombosis Research</i> , <b>1983</b> , 32, 373-9	7.3	76
1000	Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. <i>Thrombosis and Haemostasis</i> , <b>2005</b> , 93, 443-52	6.8	76
999	Diets for patients with chronic kidney disease, still worth prescribing. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2004</b> , 15, 234-7	12.3	77
998	The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance. <i>Transplantation</i> , <b>1992</b> , 54, 775-80	1.5	73

997	Proteasomal processing of albumin by renal dendritic cells generates antigenic peptides. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2009</b> , 20, 123-30	12.3	75
996	The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2008</b> , 19, 639-46	12.3	73
995	Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2008</b> , 3, 1511-25	6.7	72
994	Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2006</b> , 17, 1624-32	12.3	73
993	Permselective dysfunction of podocyte-podocyte contact upon angiotensin II unravels the molecular target for renoprotective intervention. <i>American Journal of Pathology</i> , <b>2006</b> , 168, 1073-85	5.6	72
992	Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. <i>Hypertension</i> , <b>2011</b> , 58, 776-83	8	73
991	Thrombotic Thrombocytopenic Purpura and Related Disorders. <i>Hematology/Oncology Clinics of North America</i> , <b>1990</b> , 4, 219-241	3	71
990	Adaptations and Lessons in the Province of Bergamo. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, e71	57.2	77
989	Successful liver-kidney transplantation in two children with aHUS caused by a mutation in complement factor H. <i>American Journal of Transplantation</i> , <b>2008</b> , 8, 216-21	8.4	73
988	Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA). <i>Thrombosis and Haemostasis</i> , <b>2006</b> , 95, 212-20	6.8	70
987	Proteinuria and phenotypic change of proximal tubular cells. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2003</b> , 14 Suppl 1, S36-41	12.3	72
986	A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. <i>Diabetes</i> , <b>2018</b> , 67, 1414-1427	0.7	71
985	Renal progenitors derived from human iPSCs engraft and restore function in a mouse model of acute kidney injury. <i>Scientific Reports</i> , <b>2015</b> , 5, 8826	4.7	70
984	Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol?. <i>CKJ: Clinical Kidney Journal</i> , <b>2016</b> , 9, 700-4	4.4	73
983	Mesenchymal stem cell therapy promotes renal repair by limiting glomerular podocyte and progenitor cell dysfunction in adriamycin-induced nephropathy. <i>American Journal of Physiology - Renal Physiology</i> , <b>2012</b> , 303, F1370-81	4.1	69
982	MicroRNA-324-3p promotes renal fibrosis and is a target of ACE inhibition. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2012</b> , 23, 1496-505	12.3	74
981	Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemiologici in Nefrologia (Gisen). <i>Journal of the American Society of Nephrology: JASN</i> , <b>2000</b> , 11, 88-96	12.3	67
980	Upregulation of renal and systemic cyclooxygenase-2 in patients with active lupus nephritis. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1998</b> , 9, 1202-12	12.3	65

979	Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease. <i>British Journal of Clinical Pharmacology</i> , <b>2013</b> , 76, 516-23	3.7	68
978	Rituximab for idiopathic membranous nephropathy: who can benefit?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2006</b> , 1, 738-48	6.7	69
977	Prostacyclin-like activity and bleeding in renal failure. <i>Lancet, The</i> , <b>1977</b> , 2, 1195-7	36.2	71
976	Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case-control study. <i>Nephron Clinical Practice</i> , <b>2010</b> , 115, c154-60		69
975	Imaging of the porous ultrastructure of the glomerular epithelial filtration slit. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2010</b> , 21, 2081-9	12.3	72
974	Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2017</b> , 28, 2729-2737	12.3	69
973	Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ACE inhibitor. <i>PLoS ONE</i> , <b>2013</b> , 8, e70775	3.6	68
972	Renal expression of monocyte chemoattractant protein-1 in lupus autoimmune mice. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1997</b> , 8, 720-9	12.3	64
971	A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2015</b> , 26, 209-19	12.3	67
970	Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON). <i>American Journal of Nephrology</i> , <b>2013</b> , 37, 212-22	4.4	69
969	Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2005</b> , 16 Suppl 1, S58-63	12.3	67
968	The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: evidence based on comparative studies with a receptor antagonist. <i>American Journal of Kidney Diseases</i> , <b>1997</b> , 29, 254-64	7.2	67
967	Treatment of membranous nephropathy: time for a paradigm shift. <i>Nature Reviews Nephrology</i> , <b>2017</b> , 13, 563-579	14.3	69
966	Taming the chronic kidney disease epidemic: a global view of surveillance efforts. <i>Kidney International</i> , <b>2014</b> , 86, 246-50	9.6	65
965	Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. <i>Kidney International</i> , <b>2006</b> , 70, 97-103	9.6	66
964	Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. <i>Clinical Transplantation</i> , <b>2001</b> , 15, 402-9	3.7	66
963	Effect of acetate, bicarbonate dialysis, and acetate-free biofiltration on nitric oxide synthesis: implications for dialysis hypotension. <i>American Journal of Kidney Diseases</i> , <b>1998</b> , 32, 115-24	7.2	65
962	Outrageous prices of orphan drugs: a call for collaboration. <i>Lancet, The</i> , <b>2018</b> , 392, 791-794	36.2	70

961	Progression of renal injury toward interstitial inflammation and glomerular sclerosis is dependent on abnormal protein filtration. <i>Nephrology Dialysis Transplantation</i> , <b>2015</b> , 30, 706-12	4.1	65
960	Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. <i>Kidney International</i> , <b>2014</b> , 86, 1244-52	9.6	65
959	Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2012</b> , 23, 1717-24	12.3	68
958	Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. <i>Thrombosis and Haemostasis</i> , <b>2009</b> , 101, 233-238	6.8	66
957	Pancreas and kidney/pancreas transplants: experimental medicine or real improvement?. <i>Lancet, The</i> , <b>1994</b> , 343, 27-31	36.2	67
956	Thrombotic thrombocytopenic purpura: evidence that infusion rather than removal of plasma induces remission of the disease. <i>American Journal of Kidney Diseases</i> , <b>1993</b> , 21, 314-8	7.2	65
955	Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection. <i>Nature Reviews Drug Discovery</i> , <b>2008</b> , 7, 936-53	62	65
954	Effect of angiotensin II antagonism on the regression of kidney disease in the rat. <i>Kidney International</i> , <b>2002</b> , 62, 885-94	9.6	67
953	Altered platelet and vascular prostaglandin-generation in patients with renal failure and prolonged bleeding times. <i>Thrombosis Research</i> , <b>1978</b> , 13, 1007-15	7.3	65
952	Podocytopathies. <i>Nature Reviews Disease Primers</i> , <b>2020</b> , 6, 68	49	69
951	ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2008</b> , 19, 771-9	12.3	64
950	In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. <i>Thrombosis and Haemostasis</i> , <b>2006</b> , 96, 454-464	6.8	65
949	Radial artery remodeling in response to shear stress increase within arteriovenous fistula for hemodialysis access. <i>Endothelium: Journal of Endothelial Cell Research</i> , <b>2003</b> , 10, 95-102		62
948	ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies1. <i>Kidney International</i> , <b>2000</b> , 57, 274-81	9.6	62
947	Application of newer clearance techniques for the determination of glomerular filtration rate. <i>Current Opinion in Nephrology and Hypertension</i> , <b>1998</b> , 7, 675-80	3.4	65
946	Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy. <i>Kidney International</i> , <b>1998</b> , 54, 353-9	9.6	63
945	Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab. <i>Immunobiology</i> , <b>2020</b> , 225, 152001	3.2	64
944	Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation. <i>American Journal of Transplantation</i> , <b>2005</b> , 5, 2937-44	8.4	62

943	Prevention of transplant rejection: current treatment guidelines and future developments. <i>Drugs</i> , <b>1997</b> , 54, 533-70	11.6	62
942	Increased urinary excretion of thromboxane B2 and 2,3-dinor-TxB2 in cyclosporin A nephrotoxicity. <i>Kidney International</i> , <b>1988</b> , 34, 164-74	9.6	63
941	Dose-effect and pharmacokinetics of estrogens given to correct bleeding time in uremia. <i>Kidney International</i> , <b>1988</b> , 34, 853-8	9.6	62
940	Plasmapheresis in the treatment of acute renal failure in multiple myeloma. <i>American Journal of Medicine</i> , <b>1979</b> , 66, 684-8	2.3	64
939	Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats. <i>American Journal of Pathology</i> , <b>2007</b> , 170, 1165-77	5.6	63
938	Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. <i>Kidney International</i> , <b>1998</b> , 53, 726-34	9.6	60
937	Nephrotoxic aspects of cyclosporine. <i>Transplantation Proceedings</i> , <b>2004</b> , 36, 234S-239S	1.1	59
936	Recombinant human erythropoietin to correct uremic bleeding. <i>American Journal of Kidney Diseases</i> , <b>1991</b> , 18, 44-9	7.2	60
935	Enhanced proteolysis of plasma von Willebrand factor in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. <i>Blood</i> , <b>1989</b> , 74, 978-983	2.1	59
934	Prevention of chronic kidney and vascular disease: toward global health equity--the Bellagio 2004 Declaration. <i>Kidney International</i> , <b>2005</b> , S1-6	9.6	66
933	Key fibrogenic mediators: old players. Renin-angiotensin system. <i>Kidney International Supplements</i> , <b>2014</b> , 4, 58-64	6.2	55
932	Mesenchymal stromal cells to promote solid organ transplantation tolerance. <i>Current Opinion in Organ Transplantation</i> , <b>2013</b> , 18, 51-8	2.4	59
931	Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group. <i>Transplantation</i> , <b>2009</b> , 88, 614-9	1.5	59
930	Size regulation of von Willebrand factor-mediated platelet thrombi by ADAMTS13 in flowing blood. <i>Blood</i> , <b>2006</b> , 107, 1943-50	2.1	59
929	Treatment of the hemolytic uremic syndrome with plasma. <i>Clinical Nephrology</i> , <b>1979</b> , 12, 279-84	1	59
928	Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT). <i>Transplantation</i> , <b>2010</b> , 90, 124-6	1.5	59
927	Effect of acetate-free biofiltration and bicarbonate hemodialysis on neutrophil activation. <i>American Journal of Kidney Diseases</i> , <b>2002</b> , 40, 783-93	7.2	57
926	ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome. <i>American Journal of Kidney Diseases</i> , <b>2000</b> , 35, 381-91	7.2	58

925	Long-term treatment with either enalapril or nitrendipine stabilizes albuminuria and increases glomerular filtration rate in non-insulin-dependent diabetic patients. <i>American Journal of Kidney Diseases</i> , <b>1994</b> , 24, 753-61	7.2	57
924	Cyclosporin-induced endothelial cell injury. <i>Laboratory Investigation</i> , <b>1986</b> , 55, 455-62	5.7	57
923	Membranous nephropathy associated with IgG4-related disease. <i>American Journal of Kidney Diseases</i> , <b>2011</b> , 58, 272-5	7.2	57
922	ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2009</b> , 20, 1404-15	12.3	56
921	Nephropathy of type-2 diabetes mellitus. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1998</b> , 9, 2157-69	12.3	52
920	Moderate doses of aspirin and risk of bleeding in renal failure. <i>Lancet, The</i> , <b>1986</b> , 1, 414-6	36.2	56
919	Unbalanced prostaglandin synthesis and plasma factors in uraemic bleeding. A hypothesis. <i>Thrombosis Research</i> , <b>1978</b> , 13, 531-6	7.3	58
918	Familial deficiency of a plasma factor stimulating vascular prostacyclin activity. <i>Thrombosis Research</i> , <b>1979</b> , 16, 517-25	7.3	57
917	SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy. <i>JCI Insight</i> , <b>2018</b> , 3,	9.6	56
916	Cardiovascular risk assessment in low-resource settings: a consensus document of the European Society of Hypertension Working Group on Hypertension and Cardiovascular Risk in Low Resource Settings. <i>Journal of Hypertension</i> , <b>2014</b> , 32, 951-60	1.5	59
915	In kidney transplant patients, alemtuzumab but not basiliximab/low-dose rabbit anti-thymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de novo donor-specific anti-HLA antibody development. <i>Journal of Immunology</i> , <b>2013</b> , 191, 2818-28	5.2	54
914	Chronic kidney disease: a research and public health priority. <i>Nephrology Dialysis Transplantation</i> , <b>2012</b> , 27 Suppl 3, iii19-26	4.1	53
913	Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1994</b> , 5, 1139-46	12.3	53
912	Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF. <i>American Journal of Transplantation</i> , <b>2006</b> , 6, 1617-23 <sup>8.4</sup>	8.4	55
911	Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. <i>Pediatric Nephrology</i> , <b>2015</b> , 30, 167-72	3.1	55
910	Errestin-1 drives endothelin-1-mediated podocyte activation and sustains renal injury. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2014</b> , 25, 523-33	12.3	54
909	Complement-mediated dysfunction of glomerular filtration barrier accelerates progressive renal injury. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2008</b> , 19, 1158-67	12.3	55
908	Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2006</b> , 17, 3472-81	12.3	55



907	Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. <i>Circulation</i> , <b>2003</b> , 107, 586-92	16.3	58
906	Propionyl-L-carnitine prevents renal function deterioration due to ischemia/reperfusion. <i>Kidney International</i> , <b>2002</b> , 61, 1064-78	9.6	54
905	Thymic dendritic cells express inducible nitric oxide synthase and generate nitric oxide in response to self- and alloantigens. <i>Journal of Immunology</i> , <b>2000</b> , 164, 4649-58	5.2	54
904	ACE inhibition induces regression of proteinuria and halts progression of renal damage in a genetic model of progressive nephropathy. <i>American Journal of Kidney Diseases</i> , <b>1999</b> , 34, 626-32	7.2	57
903	Nature and mediators of parietal epithelial cell activation in glomerulonephritides of human and rat. <i>American Journal of Pathology</i> , <b>2013</b> , 183, 1769-1778	5.6	53
902	Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. <i>Journal of Hypertension</i> , <b>2011</b> , 29, 207-16	1.5	54
901	Endothelin induces diuresis and natriuresis in the rat by acting on proximal tubular cells through a mechanism mediated by lipoxygenase products. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1991</b> , 2, 57-69	12.3	50
900	The regenerative potential of stem cells in acute renal failure. <i>Cell Transplantation</i> , <b>2006</b> , 15 Suppl 1, S111-7	3.8	49
899	Computational fluid dynamics of a vascular access case for hemodialysis. <i>Journal of Biomechanical Engineering</i> , <b>2001</b> , 123, 284-92	2.1	52
898	Malignant vascular disease of the kidney: nature of the lesions, mediators of disease progression, and the case for bilateral nephrectomy. <i>American Journal of Kidney Diseases</i> , <b>1996</b> , 27, 459-75	7.2	53
897	Verotoxin glycolipid receptors determine the localization of microangiopathic process in rabbits given verotoxin-1. <i>Translational Research</i> , <b>1992</b> , 120, 229-38		53
896	Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA. <i>Nephrology Dialysis Transplantation</i> , <b>2018</b> , 33, ii4-ii14	4.1	57
895	Validation of a patient-specific hemodynamic computational model for surgical planning of vascular access in hemodialysis patients. <i>Kidney International</i> , <b>2013</b> , 84, 1237-45	9.6	53
894	Angiotensin receptors as determinants of life span. <i>Pflugers Archiv European Journal of Physiology</i> , <b>2010</b> , 459, 325-32	4.5	53
893	Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2009</b> , 4, 201-6	6.7	56
892	Renal function at hospital admission as a prognostic factor in adult hemolytic uremic syndrome. The Italian Registry of Haemolytic Uremic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1992</b> , 2, 1640-4	12.3	51
891	Prediction of cyclosporine area under the curve using a three-point sampling strategy after Neoral administration. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1997</b> , 8, 647-52	12.3	50
890	Therapeutic drug monitoring of sirolimus: effect of concomitant immunosuppressive therapy and optimization of drug dosing. <i>American Journal of Transplantation</i> , <b>2004</b> , 4, 1345-51	8.4	52

889	Whole-Blood Calcineurin Activity Is Not Predicted by Cyclosporine Blood Concentration in Renal Transplant Recipients. <i>Clinical Chemistry</i> , <b>2001</b> , 47, 1679-1687	5.3	53
888	The role of protein traffic in the progression of renal diseases. <i>Annual Review of Medicine</i> , <b>2000</b> , 51, 315-328	27.8	53
887	Subcutaneous desmopressin (DDAVP) shortens the bleeding time in uremia. <i>American Journal of Hematology</i> , <b>1989</b> , 31, 32-5	6.9	52
886	Effect of short-term cyclosporine administration in rats on renin-angiotensin and thromboxane A2: possible relevance to the reduction in glomerular filtration rate. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>1986</b> , 239, 229-35	4.5	52
885	Fluid shear stress modulates surface expression of adhesion molecules by endothelial cells. <i>Blood</i> , <b>1995</b> , 85, 1696-703	2.1	52
884	Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes. <i>American Journal of Physiology - Renal Physiology</i> , <b>2011</b> , 301, F1114-23	4.1	52
883	The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1998</b> , 9, 2308-17	12.3	50
882	Screening for complement system abnormalities in patients with atypical hemolytic uremic syndrome. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2007</b> , 2, 591-6	6.7	51
881	Involvement of renal tubular Toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 1569-78		53
880	Platelets: an update on diagnosis and management of thrombocytopenic disorders. <i>Hematology American Society of Hematology Education Program</i> , <b>2001</b> , 282-305	2.9	50
879	Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. <i>Blood</i> , <b>2005</b> , 106, 925-8	2.1	51
878	Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-beta in experimental mesangioproliferative glomerulonephritis. <i>American Journal of Kidney Diseases</i> , <b>1998</b> , 31, 453-63	7.2	51
877	Antibody-mediated extraction/negative-ion chemical ionization mass spectrometric measurement of thromboxane B2 and 2,3-dinor-thromboxane B2 in human and rat urine. <i>Analytical Biochemistry</i> , <b>1987</b> , 163, 255-62	3	51
876	Organoid Models and Applications in Biomedical Research. <i>Nephron</i> , <b>2015</b> , 130, 191-9	3.1	51
875	Effective CKD care in European countries: challenges and opportunities for health policy. <i>American Journal of Kidney Diseases</i> , <b>2015</b> , 65, 15-25	7.2	58
874	Renal progenitors in non-diabetic and diabetic nephropathies. <i>Trends in Endocrinology and Metabolism</i> , <b>2013</b> , 24, 13-20	8.5	50
873	Burden of CKD, proteinuria, and cardiovascular risk among Chinese, Mongolian, and Nepalese participants in the International Society of Nephrology screening programs. <i>American Journal of Kidney Diseases</i> , <b>2010</b> , 56, 915-27	7.2	49
872	Proteinuria predicting outcome in renal disease: nondiabetic nephropathies (REIN). <i>Kidney International</i> , <b>2004</b> , S90-6	9.6	48

871	Is ADAMTS-13 deficiency specific for thrombotic thrombocytopenic purpura? No. <i>Journal of Thrombosis and Haemostasis</i> , <b>2003</b> , 1, 632-4	15	51
870	A comparative prospective study of two available solutions for kidney and liver preservation. <i>Transplantation</i> , <b>2004</b> , 77, 1540-5	1.5	49
869	Prevention and treatment of pregnancy-associated hypertension: what have we learned in the last 10 years?. <i>American Journal of Kidney Diseases</i> , <b>1991</b> , 18, 285-305	7.2	50
868	Generation of functional podocytes from human induced pluripotent stem cells. <i>Stem Cell Research</i> , <b>2016</b> , 17, 130-9	1.5	50
867	Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study. <i>American Journal of Nephrology</i> , <b>2011</b> , 33, 461-8	4.4	51
866	CTLA4Ig gene transfer prolongs survival and induces donor-specific tolerance in a rat renal allograft. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2000</b> , 11, 747-752	12.3	48
865	Hemolytic uremic syndrome: a factor H mutation (E1172Stop) causes defective complement control at the surface of endothelial cells. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2007</b> , 18, 506-14	12.3	49
864	From pharmacokinetics to pharmacogenomics: a new approach to tailor immunosuppressive therapy. <i>American Journal of Transplantation</i> , <b>2004</b> , 4, 299-310	8.4	48
863	Indomethacin reduces proteinuria in passive Heymann nephritis in rats. <i>Kidney International</i> , <b>1987</b> , 31, 1335-43	9.6	50
862	Haemolytic uraemic syndrome: therapeutic effect of plasma infusion. <i>British Medical Journal</i> , <b>1982</b> , 285, 1304-6		52
861	Italy's first wave of the COVID-19 pandemic has ended: no excess mortality in May, 2020. <i>Lancet, The</i> , <b>2020</b> , 396, e27-e28	36.2	47
860	Timed urine collections are not needed to measure urine protein excretion in clinical practice. <i>American Journal of Kidney Diseases</i> , <b>2006</b> , 47, 1-7	7.2	49
859	Blunted excretory response to atrial natriuretic peptide in experimental nephrosis. <i>Kidney International</i> , <b>1989</b> , 36, 57-64	9.6	46
858	Enhanced proteolysis of plasma von Willebrand factor in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. <i>Blood</i> , <b>1989</b> , 74, 978-983	2.1	48
857	Renal injury induced by long-term administration of cyclosporin A to rats. <i>American Journal of Pathology</i> , <b>1987</b> , 127, 569-79	5.6	48
856	Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 1199-1208	6.5	47
855	Extracellular vesicles derived from T regulatory cells suppress T cell proliferation and prolong allograft survival. <i>Scientific Reports</i> , <b>2017</b> , 7, 11518	4.7	47
854	Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , <b>2009</b> , 54, 59-69	7.2	48

853	Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2007</b> , 2, 1147-55	6.7	46
852	Evidence against a pathogenetic role for endothelin in pre-eclampsia. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>1992</b> , 99, 798-802	3.5	48
851	Human placenta expresses endothelin gene and corresponding protein is excreted in urine in increasing amounts during normal pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , <b>1991</b> , 164, 844-8	1.9	48
850	Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2018</b> , 29, 283-294	12.3	48
849	V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction. <i>Kidney International</i> , <b>2009</b> , 76, 960-7	9.6	42
848	How renal cytokines and growth factors contribute to renal disease progression. <i>American Journal of Kidney Diseases</i> , <b>2001</b> , 37, S21-4	7.2	46
847	Bleeding in renal failure: is von Willebrand factor implicated?. <i>The BMJ</i> , <b>1977</b> , 2, 359-61		47
846	Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2016</b> , 18, 64-71	6.5	44
845	Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2013</b> , 22, 704-12	3.4	46
844	Glomerular filtration rate determined from a single plasma sample after intravenous iohexol injection: is it reliable?. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1996</b> , 7, 2689-93	12.3	43
843	Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. <i>Kidney International</i> , <b>2001</b> , 60, 653-63	9.6	44
842	Nephrotoxicity of increased glomerular protein traffic. <i>Nephrology Dialysis Transplantation</i> , <b>1999</b> , 14, 304-12	4.1	45
841	Three-dimensional analysis of glomerular morphology in patients with subtotal nephrectomy. <i>Kidney International</i> , <b>1995</b> , 48, 155-62	9.6	46
840	Atrial natriuretic peptide and prostacyclin synergistically mediate hyperfiltration and hyperperfusion of diabetic rats. <i>Diabetes</i> , <b>1992</b> , 41, 533-8	0.7	45
839	Functional Human Podocytes Generated in Organoids from Amniotic Fluid Stem Cells. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2016</b> , 27, 1400-11	12.3	44
838	Paricalcitol for secondary hyperparathyroidism in renal transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2015</b> , 26, 1205-14	12.3	44
837	Cardiovascular complications in atypical haemolytic uraemic syndrome. <i>Nature Reviews Nephrology</i> , <b>2014</b> , 10, 174-80	14.3	45
836	Kidney failure: aims for the next 10 years and barriers to success. <i>Lancet, The</i> , <b>2013</b> , 382, 353-62	36.2	45

835	Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection. <i>American Journal of Physiology - Renal Physiology</i> , <b>2010</b> , 299, F1203-11	4.1	44
834	Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2008</b> , 3, 1652-9	6.7	46
833	Nephropathic nature of proteinuria. <i>Current Opinion in Nephrology and Hypertension</i> , <b>1999</b> , 8, 655-63	3.4	45
832	Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade. <i>Kidney International</i> , <b>1999</b> , 55, 984-94	9.6	44
831	PAF mediates neutrophil adhesion to thrombin or TNF-stimulated endothelial cells under shear stress. <i>American Journal of Physiology - Cell Physiology</i> , <b>1995</b> , 269, C42-7	5.2	44
830	MicroRNA-184 is a downstream effector of albuminuria driving renal fibrosis in rats with diabetic nephropathy. <i>Diabetologia</i> , <b>2017</b> , 60, 1114-1125	10	43
829	The Toll-IL-1R member Tir8/SIGIRR negatively regulates adaptive immunity against kidney grafts. <i>Journal of Immunology</i> , <b>2009</b> , 183, 4249-60	5.2	43
828	Sequential monitoring of urine-soluble interleukin 2 receptor and interleukin 6 predicts acute rejection of human renal allografts before clinical or laboratory signs of renal dysfunction. <i>Transplantation</i> , <b>1997</b> , 63, 1508-14	1.5	43
827	Biocompatibility and function of microencapsulated pancreatic islets. <i>Acta Biomaterialia</i> , <b>2006</b> , 2, 221-7	10.5	43
826	Thrombotic thrombocytopenic purpura--then and now. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2006</b> , 32, 81-9	5.1	40
825	Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy. <i>Kidney International</i> , <b>2004</b> , 66, 1959-65	9.6	44
824	Platelet activating factor (PAF) as a mediator of injury in nephrotoxic nephritis. <i>Kidney International</i> , <b>1987</b> , 31, 1248-56	9.6	43
823	Plasmatic regulation of vascular prostacyclin in pregnancy. <i>British Medical Journal</i> , <b>1981</b> , 282, 512-4		43
822	Renal and Systemic Effects of Calorie Restriction in Patients With Type 2 Diabetes With Abdominal Obesity: A Randomized Controlled Trial. <i>Diabetes</i> , <b>2017</b> , 66, 75-86	0.7	43
821	Long-term follow-up of recovered patients with COVID-19. <i>Lancet, The</i> , <b>2021</b> , 397, 173-175	36.2	46
820	Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 1629-37		42
819	Increased Fragmentation of von Willebrand Factor, Due to Abnormal Cleavage of the Subunit, Parallels Disease Activity in Recurrent Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura and Discloses Predisposition in Families. <i>Blood</i> , <b>1999</b> , 94, 610-620	2.1	42
818	Colchicine interferes with L-selectin and leukocyte function-associated antigen-1 expression on human T lymphocytes and inhibits T cell activation. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1996</b> , 7, 594-601	12.3	34

817	Abnormal permeability to proteins and glomerular lesions: a meta-analysis of experimental and human studies. <i>American Journal of Kidney Diseases</i> , <b>1996</b> , 27, 34-41	7.2	42
816	Increased nitric oxide formation in recurrent thrombotic microangiopathies: a possible mediator of microvascular injury. <i>American Journal of Kidney Diseases</i> , <b>1996</b> , 27, 790-6	7.2	41
815	Low-protein diet prevents glomerular damage in adriamycin-treated rats. <i>Kidney International</i> , <b>1985</b> , 28, 21-7	9.6	41
814	Long-Term Clinical and Immunological Profile of Kidney Transplant Patients Given Mesenchymal Stromal Cell Immunotherapy. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 1359	8.2	41
813	Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations. <i>American Journal of Transplantation</i> , <b>2013</b> , 13, 2201-6	8.4	39
812	Targeted downregulation of extracellular nephrin in human IgA nephropathy. <i>American Journal of Nephrology</i> , <b>2003</b> , 23, 277-86	4.4	40
811	The first clinical and epidemiological programme on renal disease in Bolivia: a model for prevention and early diagnosis of renal diseases in the developing countries. <i>Nephrology Dialysis Transplantation</i> , <b>1998</b> , 13, 3034-6	4.1	44
810	Protein overload activates proximal tubular cells to release vasoactive and inflammatory mediators. <i>Nephron Experimental Nephrology</i> , <b>1999</b> , 7, 420-8		40
809	Coagulation abnormalities in uremia. <i>Seminars in Nephrology</i> , <b>1985</b> , 5, 82-90	4.6	40
808	Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2014</b> , 25, 1786-98	12.3	39
807	Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort study. <i>PLoS ONE</i> , <b>2012</b> , 7, e32533	3.6	41
806	Sirolimus for calcineurin inhibitors in organ transplantation: contra. <i>Kidney International</i> , <b>2010</b> , 78, 1068-74		40
805	Correction of anemia--payoffs and problems. <i>New England Journal of Medicine</i> , <b>2006</b> , 355, 2144-6	57.2	43
804	Tackling the shortage of donor kidneys: how to use the best that we have. <i>American Journal of Nephrology</i> , <b>2003</b> , 23, 245-59	4.4	36
803	Changes in glomerular perm-selectivity induced by angiotensin II imply podocyte dysfunction and slit diaphragm protein rearrangement. <i>Seminars in Nephrology</i> , <b>2004</b> , 24, 131-40	4.6	40
802	Angiotensin-converting enzyme inhibition prevents glomerular-tubule disconnection and atrophy in passive Heymann nephritis, an effect not observed with a calcium antagonist. <i>American Journal of Pathology</i> , <b>2001</b> , 159, 1743-50	5.6	40
801	Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model. <i>American Journal of Kidney Diseases</i> , <b>1999</b> , 33, 746-53	7.2	39
800	Experimental Goodpasture's syndrome in Wistar-Kyoto rats immunized with alpha3 chain of type IV collagen. <i>Kidney International</i> , <b>1998</b> , 54, 1550-61	9.6	38

799	Bilateral nephrectomy stopped disease progression in plasma-resistant hemolytic uremic syndrome with neurological signs and coma. <i>Kidney International</i> , <b>1996</b> , 49, 282-6	9.6	39
798	Plasma exchange in children with hemolytic-uremic syndrome at risk of poor outcome. <i>American Journal of Kidney Diseases</i> , <b>1993</b> , 22, 264-6	7.2	39
797	Parathyroid hormone inhibits human platelet function. <i>Lancet, The</i> , <b>1981</b> , 2, 1321-3	36.2	39
796	Thrombotic tendency in systemic lupus erythematosus. <i>Lancet, The</i> , <b>1981</b> , 1, 719	36.2	39
795	Pathophysiology and management of thrombotic microangiopathies. <i>Journal of Nephrology</i> , <b>1998</b> , 11, 300-10	4.6	39
794	The effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials. <i>BMC Nephrology</i> , <b>2016</b> , 17, 141	2.6	39
793	Podocyte dysfunction in atypical haemolytic uraemic syndrome. <i>Nature Reviews Nephrology</i> , <b>2015</b> , 11, 245-52	14.3	38
792	Variations of the angiotensin II type 1 receptor gene are associated with extreme human longevity. <i>Age</i> , <b>2013</b> , 35, 993-1005		37
791	Prevention programmes of progressive renal disease in developing nations. <i>Nephrology</i> , <b>2006</b> , 11, 321-8.2.2		41
790	Doppler ultrasonography in posttransplant renal artery stenosis: a reliable tool for assessing effectiveness of revascularization?. <i>Transplantation</i> , <b>2003</b> , 76, 147-53	1.5	37
789	Halting the progression of chronic nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2002</b> , 13 Suppl 3, S190-5	12.3	37
788	Mesenchymal Stem Cells in Kidney Repair. <i>Methods in Molecular Biology</i> , <b>2016</b> , 1416, 89-107	1.4	36
787	Characterization of a New DGKE Intronic Mutation in Genetically Unsolved Cases of Familial Atypical Hemolytic Uremic Syndrome. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2015</b> , 10, 1011-9	6.7	37
786	Long-term outcome of renal transplantation from octogenarian donors: A multicenter controlled study. <i>American Journal of Transplantation</i> , <b>2017</b> , 17, 3159-3171	8.4	35
785	Clinical Translation of Mesenchymal Stromal Cell Therapies in Nephrology. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2018</b> , 29, 362-375	12.3	38
784	Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy. <i>American Journal of Kidney Diseases</i> , <b>2018</b> , 71, 91-101	7.2	37
783	Acute renal failure: an unacceptable death sentence globally. <i>Lancet, The</i> , <b>2013</b> , 382, 2041-2	36.2	39
782	Polymorphisms of EDNRB, ATG, and ACE genes in salt-sensitive hypertension. <i>Canadian Journal of Physiology and Pharmacology</i> , <b>2008</b> , 86, 505-10	2.4	37

781	Albuminuria as early test for vascular disease. <i>Lancet, The</i> , <b>2005</b> , 365, 556-557	36.2	38
780	Mesenchymal Stromal Cells for Transplant Tolerance. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 1287	8.2	36
779	Progression of chronic kidney disease: insights from animal models. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2006</b> , 15, 250-7	3.4	35
778	Angiotensin II blockade limits tubular protein overreabsorption and the consequent upregulation of endothelin 1 gene in experimental membranous nephropathy. <i>Nephron Experimental Nephrology</i> , <b>1998</b> , 6, 121-31		35
777	An ExVivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome. <i>American Journal of Kidney Diseases</i> , <b>2019</b> , 74, 56-72	7.2	35
776	Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials. <i>Lancet, The</i> , <b>2015</b> , 385, 867-74	36.2	35
775	Effects of MCP-1 inhibition by bindarit therapy in a rat model of polycystic kidney disease. <i>Nephron</i> , <b>2015</b> , 129, 52-61	3.1	35
774	Diets for patients with chronic kidney disease, should we reconsider?. <i>BMC Nephrology</i> , <b>2016</b> , 17, 80	2.6	37
773	Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis. <i>Journal of Immunology</i> , <b>2017</b> , 199, 1021-1040	5.2	34
772	Antiproteinuric effect of chemokine C-C motif ligand 2 inhibition in subjects with acute proliferative lupus nephritis. <i>American Journal of Nephrology</i> , <b>2011</b> , 34, 367-72	4.4	35
771	Fractalkine and CX3CR1 mediate leukocyte capture by endothelium in response to Shiga toxin. <i>Journal of Immunology</i> , <b>2008</b> , 181, 1460-9	5.2	35
770	Beneficial effect of TGFbeta antagonism in treating diabetic nephropathy depends on when treatment is started. <i>Nephron Experimental Nephrology</i> , <b>2006</b> , 104, e158-68		35
769	Genetic analysis of the complement factor H related 5 gene in haemolytic uraemic syndrome. <i>Molecular Immunology</i> , <b>2007</b> , 44, 1704-8	4.2	35
768	The June 2003 Barry M. Brenner Comgan lecture. The future of renoprotection: frustration and promises. <i>Kidney International</i> , <b>2003</b> , 64, 1947-55	9.6	37
767	Structural basis of diabetic nephropathy in microalbuminuric NIDDM patients: a light microscopy study. <i>Diabetologia</i> , <b>1996</b> , 39, 1625-8	10	36
766	Edema of the nephrotic syndrome: the role of the atrial peptide system. <i>American Journal of Kidney Diseases</i> , <b>1993</b> , 22, 355-66	7.2	35
765	Prostacyclin generation by cultured endothelial cells in haemolytic uraemic syndrome. <i>Lancet, The</i> , <b>1980</b> , 1, 656-7	36.2	38
764	Mesenchymal stromal cells for tolerance induction in organ transplantation. <i>Human Immunology</i> , <b>2018</b> , 79, 304-313	2.2	35



763	Aging and the kidney. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2011</b> , 20, 312-7	3.4	34
762	The role of chemokines in progressive renal disease. <i>Frontiers in Bioscience - Landmark</i> , <b>2009</b> , 14, 1815-22.7		34
761	Ways to boost kidney transplant viability: a real need for the best use of older donors. <i>American Journal of Transplantation</i> , <b>2006</b> , 6, 2543-7	8.4	34
760	Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2006</b> , 1, 546-54	6.7	34
759	Cellular basis of long-term organ transplant acceptance: pivotal role of intrathymic clonal deletion and thymic dependence of bone marrow microchimerism-associated tolerance. <i>American Journal of Kidney Diseases</i> , <b>1998</b> , 31, 197-212	7.2	34
758	Prevention of renal injury in diabetic MWF rats by angiotensin II antagonism. <i>Nephron Experimental Nephrology</i> , <b>1998</b> , 6, 28-38		34
757	Proteinuria as a mediator of tubulointerstitial injury. <i>Kidney and Blood Pressure Research</i> , <b>1999</b> , 22, 37-46.9		34
756	Deficiency Shortens Life Span and Impairs Cardiac Mitochondrial Function Rescued by Gene Transfer. <i>Antioxidants and Redox Signaling</i> , <b>2019</b> , 31, 1255-1271	8	33
755	Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?. <i>American Journal of Physiology - Renal Physiology</i> , <b>2016</b> , 310, F335-41	4.1	36
754	Physiology and pathophysiology of nitric oxide in chronic renal disease. <i>Proceedings of the Association of American Physicians</i> , <b>1999</b> , 111, 602-10		33
753	Insulin resistance and proliferative retinopathy: a cross-sectional, case-control study in 115 patients with type 2 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 4371-6	5.4	33
752	Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. <i>Kidney International</i> , <b>2001</b> , 59, 286-94	9.6	32
751	Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 1022-1030.e4	6.6	33
750	Rare diseases and effective treatments: are we delivering?. <i>Lancet, The</i> , <b>2015</b> , 385, 750-2	36.2	33
749	Rituximab in primary membranous nephropathy: first-line therapy, why not?. <i>Nephron Clinical Practice</i> , <b>2014</b> , 128, 261-9		32
748	Angiotensin II contributes to diabetic renal dysfunction in rodents and humans via Notch1/Snail pathway. <i>American Journal of Pathology</i> , <b>2013</b> , 183, 119-30	5.6	31
747	Effect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathy. <i>Hypertension</i> , <b>2010</b> , 55, 1206-9	8	32
746	Experimental Evaluation of Kidney Regeneration by Organ Scaffold Recellularization. <i>Scientific Reports</i> , <b>2017</b> , 7, 43502	4.7	32

745	Direct podocyte damage in the single nephron leads to albuminuria in vivo. <i>Kidney International</i> , <b>1995</b> , 47, 1078-86	9.6	32
744	Thromboxane A2 receptor blocking abrogates donor-specific unresponsiveness to renal allografts induced by thymic recognition of major histocompatibility allopeptides. <i>Journal of Experimental Medicine</i> , <b>1994</b> , 180, 1967-72	16.2	32
743	Increased renal endothelin production in rats with reduced renal mass. <i>American Journal of Physiology - Renal Physiology</i> , <b>1991</b> , 260, F331-9	4.1	31
742	Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. <i>American Journal of Kidney Diseases</i> , <b>2004</b> , 44, 385-401	7.2	32
741	Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2013</b> , 1, 19-27	17.4	31
740	Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2010</b> , 5, 1928-38	6.7	31
739	Ethical issues in dialysis therapy. <i>Lancet, The</i> , <b>2017</b> , 389, 1851-1856	36.2	30
738	Developing regulatory-compliant electronic case report forms for clinical trials: experience with the demand trial. <i>Journal of the American Medical Informatics Association: JAMIA</i> , <b>2009</b> , 16, 404-8	8.3	31
737	Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver/kidney transplant recipient. <i>Journal of Clinical Gastroenterology</i> , <b>2007</b> , 41, 216-20	2.9	31
736	Association of functional gene variants in the regulatory regions of COX-2 gene (PTGS2) with nonmelanoma skin cancer after organ transplantation. <i>British Journal of Dermatology</i> , <b>2007</b> , 157, 49-57	3	30
735	Renoprotective effect of low iron diet and its consequence on glomerular hemodynamics. <i>Kidney International</i> , <b>1991</b> , 39, 647-52	9.6	31
734	The metabolism of arachidonic acid by platelets in nephrotic syndrome. <i>Kidney International</i> , <b>1984</b> , 25, 671-6	9.6	31
733	Reduction of fetal vascular prostacyclin activity in pre-eclampsia. <i>Lancet, The</i> , <b>1980</b> , 2, 310	36.2	32
732	Therapy with a Selective Cannabinoid Receptor Type 2 Agonist Limits Albuminuria and Renal Injury in Mice with Type 2 Diabetic Nephropathy. <i>Nephron</i> , <b>2016</b> , 132, 59-69	3.1	30
731	The role of renin angiotensin system inhibition in kidney repair. <i>Fibrogenesis and Tissue Repair</i> , <b>2010</b> , 3, 7		29
730	Thromboxane receptor blockade attenuates chronic cyclosporine nephrotoxicity and improves survival in rats with renal isograft. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1992</b> , 2, 1398-404	12.3	28
729	Protecting single-kidney allografts from long-term functional deterioration. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1998</b> , 9, 1321-32	12.3	28
728	High-performance liquid chromatography with ultraviolet detection for therapeutic drug monitoring of everolimus. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2005</b> , 816, 99-105	3.1	30

727	Strategies for national health care systems in emerging countries: the case of screening and prevention of renal disease progression in Bolivia. <i>Kidney International</i> , <b>2005</b> , S87-94	9.6	37
726	Role of platelets in progressive glomerular diseases. <i>Pediatric Nephrology</i> , <b>1995</b> , 9, 495-502	3.1	30
725	Glomerular hyperfiltration and urinary prostaglandins in type 1 diabetes mellitus. <i>Diabetic Medicine</i> , <b>1989</b> , 6, 219-23	3.4	29
724	Incidence and clinical predictors of Kaposi's sarcoma among 1721 Italian solid organ transplant recipients: a multicenter study. <i>European Journal of Dermatology</i> , <b>2006</b> , 16, 553-7	0.7	30
723	Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice. <i>Journal of Immunology</i> , <b>2012</b> , 189, 3661-8	5.2	29
722	Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT). <i>Diabetes Care</i> , <b>2008</b> , 31, 1629-34	14.1	29
721	Immunosuppressive treatment for focal segmental glomerulosclerosis in adults. <i>The Cochrane Library</i> , <b>2008</b> , CD003233	4.9	29
720	The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristics. <i>American Journal of Nephrology</i> , <b>2009</b> , 30, 280-6	4.4	29
719	Combined treatment with mycophenolate mofetil and an angiotensin II receptor antagonist fully protects from chronic rejection in a rat model of renal allograft. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2001</b> , 12, 1937-1946	12.3	29
718	Prevention and treatment of diabetic retinopathy: evidence from clinical trials and perspectives. <i>Current Diabetes Reviews</i> , <b>2011</b> , 7, 190-200	2.5	29
717	Adeno-associated virus-mediated CTLA4Ig gene transfer protects MHC-mismatched renal allografts from chronic rejection. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2006</b> , 17, 1665-72	12.3	29
716	Overview of randomised trials of ACE inhibitors. <i>Lancet, The</i> , <b>2006</b> , 368, 555-6	36.2	29
715	Peripheral donor leukocytes prolong survival of rat renal allografts. <i>Kidney International</i> , <b>1999</b> , 56, 1101-1108	3.2	29
714	Cyclosporine induces glomerulosclerosis: three-dimensional definition of the lesions in a rat model of renal transplant. <i>Kidney International</i> , <b>1996</b> , 49, 1283-8	9.6	29
713	Prostacyclin and thrombotic microangiopathy. <i>Seminars in Thrombosis and Hemostasis</i> , <b>1980</b> , 6, 391-4	5.1	29
712	Platelet function in patients on maintenance hemodialysis: depressed or enhanced?. <i>Clinical Nephrology</i> , <b>1982</b> , 17, 60-3	1	29
711	Verotoxin-1 promotes leukocyte adhesion to cultured endothelial cells under physiologic flow conditions. <i>Blood</i> , <b>1995</b> , 86, 4553-8	2.1	29
710	Regression of Renal Disease by Angiotensin II Antagonism Is Caused by Regeneration of Kidney Vasculature. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2016</b> , 27, 699-705	12.3	28

709	Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2015</b> , 10, 1568-74	6.7	27
708	Blood pressure, proteinuria, and phosphate as risk factors for progressive kidney disease: a hypothesis. <i>American Journal of Kidney Diseases</i> , <b>2013</b> , 62, 984-92	7.2	29
707	Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injury. <i>Kidney International</i> , <b>2012</b> , 81, 903-18	9.6	29
706	Preventing renal and cardiovascular risk by renal function assessment: insights from a cross-sectional study in low-income countries and the USA. <i>BMJ Open</i> , <b>2012</b> , 2,	2.9	27
705	Computed tomography evaluation of autosomal dominant polycystic kidney disease progression: a progress report. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2006</b> , 1, 754-60	6.7	28
704	Targeted deletion of angiotensin II type 1A receptor does not protect mice from progressive nephropathy of overload proteinuria. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2004</b> , 15, 2666-74	12.2	28
703	ACE inhibition versus angiotensin receptor blockade: which is better for renal and cardiovascular protection?. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2004</b> , 15 Suppl 1, S64-70	12.3	28
702	Remission achieved in chronic nephropathy by a multidrug approach targeted at urinary protein excretion. <i>Nephron</i> , <b>2001</b> , 88, 254-9	3.1	29
701	The hemolytic uremic syndromes. <i>Current Opinion in Critical Care</i> , <b>2005</b> , 11, 487-92	3.4	28
700	Dendritic cells genetically engineered with adenoviral vector encoding dnIKK2 induce the formation of potent CD4+ T-regulatory cells. <i>Transplantation</i> , <b>2005</b> , 79, 1056-61	1.5	28
699	Cigarette smoking and renal function impairment. <i>American Journal of Kidney Diseases</i> , <b>1999</b> , 33, 807-13	7.2	29
698	Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. <i>American Journal of Nephrology</i> , <b>2014</b> , 40, 572-81	4.4	27
697	Renoprotective effects of renin-angiotensin-system inhibitors. <i>Lancet, The</i> , <b>2006</b> , 367, 899-900; author reply 900-2	36.2	27
696	Adult nondiarrhea hemolytic uremic syndrome associated with Shiga toxin Escherichia coli O157:H7 bacteremia and urinary tract infection. <i>American Journal of Kidney Diseases</i> , <b>2003</b> , 41, e4.1 - e4.4	7.2	27
695	Following an initial decline, glomerular filtration rate stabilizes in heart transplant patients on chronic cyclosporine. <i>American Journal of Kidney Diseases</i> , <b>1994</b> , 24, 549-53	7.2	27
694	Time course and localization of endothelin-1 gene expression in a model of renal disease progression. <i>American Journal of Pathology</i> , <b>1997</b> , 151, 1241-7	5.6	27
693	Measurement of glomerular filtration rate. <i>Kidney International, Supplement</i> , <b>1997</b> , 63, S151-4		28
692	Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers. <i>European Journal of Preventive Cardiology</i> , <b>2016</b> , 23, 758-68	3.8	27

691	Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120. <i>Clinical and Experimental Nephrology</i> , <b>2018</b> , 22, 299-308	2.4	27
690	CD133+ renal stem cells always co-express CD24 in adult human kidney tissue. <i>Stem Cell Research</i> , <b>2014</b> , 12, 828-9	1.5	26
689	Rare diseases: what's next?. <i>Lancet, The</i> , <b>2008</b> , 371, 1978-9	36.2	27
688	Endothelin antagonists and renal protection. <i>Journal of Cardiovascular Pharmacology</i> , <b>2000</b> , 35, S75-78	3.1	26
687	Pretransplant donor peripheral blood mononuclear cells infusion induces transplantation tolerance by generating regulatory T cells. <i>Transplantation</i> , <b>2005</b> , 79, 1034-9	1.5	26
686	Beneficial effects of calcium channel blockade on acute glomerular hemodynamic changes induced by cyclosporine. <i>American Journal of Kidney Diseases</i> , <b>1999</b> , 33, 267-75	7.2	26
685	Measurement of GFR with a single intravenous injection of nonradioactive iothalamate. <i>Kidney International</i> , <b>1992</b> , 41, 1081-4	9.6	26
684	Catecholamine receptor binding in rat kidney: effect of aging. <i>Kidney International</i> , <b>1988</b> , 33, 1073-7	9.6	26
683	Renal biopsy in patients with acute renal failure and prolonged bleeding time: a preliminary report. <i>American Journal of Kidney Diseases</i> , <b>1985</b> , 6, 397-9	7.2	26
682	Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2016</b> , 11, 785-94	6.7	25
681	Direct reprogramming of human bone marrow stromal cells into functional renal cells using cell-free extracts. <i>Stem Cell Reports</i> , <b>2015</b> , 4, 685-98	7.8	25
680	Mesenchymal stromal cells to promote kidney transplantation tolerance. <i>Current Opinion in Organ Transplantation</i> , <b>2014</b> , 19, 47-53	2.4	25
679	Erythropoietin enhances immunostimulatory properties of immature dendritic cells. <i>Clinical and Experimental Immunology</i> , <b>2011</b> , 165, 202-10	5.9	25
678	COVID-19 and lombardy: TESTING the impact of the first wave of the pandemic. <i>EBioMedicine</i> , <b>2020</b> , 61, 103069	8.6	25
677	Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT. <i>Diabetes</i> , <b>2009</b> , 58, 2920-9	0.7	25
676	Immunophenotypic analysis of cellular infiltrate of renal allograft biopsies in patients with acute rejection after induction with alemtuzumab (Campath-1H). <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2006</b> , 1, 539-45	6.7	26
675	Clinical update: immunosuppression minimisation. <i>Lancet, The</i> , <b>2007</b> , 369, 1676-8	36.2	26
674	ACE inhibition limits chronic injury of kidney transplant even with treatment started when lesions are established. <i>Kidney International</i> , <b>2003</b> , 64, 2253-61	9.6	26

673	Post-transplant renal artery stenosis: the hemodynamic response to revascularization. <i>Kidney International</i> , <b>2001</b> , 60, 309-18	9.6	25
672	A report with consensus statements of the International Society of Nephrology 2004 Consensus Workshop on Prevention of Progression of Renal Disease, Hong Kong, June 29, 2004. <i>Kidney International</i> , <b>2005</b> , S2-7	9.6	40
671	Shear stress-induced cytoskeleton rearrangement mediates NF-kappaB-dependent endothelial expression of ICAM-1. <i>Microvascular Research</i> , <b>2000</b> , 60, 182-8	3.6	25
670	Sympathetic overactivity in hypertensive patients with chronic renal disease. <i>New England Journal of Medicine</i> , <b>1999</b> , 340, 1360-1	57.2	25
669	Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy. Technical note. <i>Kidney International</i> , <b>1998</b> , 54, 2146-50	9.6	25
668	Toward novel antirejection strategies: in vivo immunosuppressive properties of CTLA4Ig. <i>Kidney International</i> , <b>1995</b> , 47, 241-6	9.6	25
667	Neurological symptoms and coma associated with doxorubicin administration during chronic cyclosporin therapy. <i>Lancet, The</i> , <b>1992</b> , 339, 1421	36.2	25
666	Novel Biomarkers for Renal Diseases? None for the Moment (but One). <i>Journal of Biomolecular Screening</i> , <b>2016</b> , 21, 655-70		25
665	Engineering the vasculature of decellularized rat kidney scaffolds using human induced pluripotent stem cell-derived endothelial cells. <i>Scientific Reports</i> , <b>2019</b> , 9, 8001	4.7	24
664	A German outbreak of haemolytic uraemic syndrome. <i>Lancet, The</i> , <b>2011</b> , 378, 1057-8	36.2	26
663	Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial. <i>Diabetes Care</i> , <b>2010</b> , 33, 1954-6	14.1	25
662	Protein load impairs factor H binding promoting complement-dependent dysfunction of proximal tubular cells. <i>Kidney International</i> , <b>2009</b> , 75, 1050-9	9.6	24
661	Outcome of renal transplantation from very old donors. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 1464-5	57.2	24
660	Thromboxane synthesis inhibition increases renal prostacyclin and prevents renal disease progression in rats with remnant kidney. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1990</b> , 1, 799-807	12.3	23
659	Generic cyclosporine formulations: more open questions than answers. <i>Transplant International</i> , <b>2005</b> , 18, 371-8	2.9	24
658	Angiotensin-converting enzyme inhibitor therapy for non-diabetic progressive renal disease. <i>Current Opinion in Nephrology and Hypertension</i> , <b>1997</b> , 6, 489-95	3.4	25
657	New insights into circulating cell-endothelium interactions and their significance for glomerular pathophysiology. <i>American Journal of Kidney Diseases</i> , <b>1995</b> , 26, 541-8	7.2	24
656	Cyclosporine enhances leukocyte adhesion to vascular endothelium under physiologic flow conditions. <i>American Journal of Kidney Diseases</i> , <b>1996</b> , 28, 23-31	7.2	24

655	Urinary excretion of platelet-activating factor in haemolytic uraemic syndrome. <i>Lancet, The</i> , <b>1992</b> , 339, 835-6	36.2	25
654	Ticlopidine prevents renal disease progression in rats with reduced renal mass. <i>Kidney International</i> , <b>1990</b> , 37, 934-42	9.6	25
653	Glomerular protein trafficking and progression of renal disease to terminal uremia. <i>Seminars in Nephrology</i> , <b>1996</b> , 16, 151-9	4.6	24
652	Maternal and environmental risk factors for neonatal AKI and its long-term consequences. <i>Nature Reviews Nephrology</i> , <b>2018</b> , 14, 688-703	14.3	23
651	PPAR $\alpha$ P12A polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case-control studies. <i>Nephrology Dialysis Transplantation</i> , <b>2011</b> , 26, 4011-6	4.1	23
650	ADAMTS13 predicts renal and cardiovascular events in type 2 diabetic patients and response to therapy. <i>Diabetes</i> , <b>2013</b> , 62, 3599-609	0.7	23
649	Genetics and genetic testing in hemolytic uremic syndrome/thrombotic thrombocytopenic purpura. <i>Seminars in Nephrology</i> , <b>2010</b> , 30, 395-408	4.6	23
648	Decision time for pancreatic islet-cell transplantation. <i>Lancet, The</i> , <b>2008</b> , 371, 883-4	36.2	24
647	Common Elements in Rare Kidney Diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , <b>2017</b> , 92, 796-808	9.6	25
646	Post-transplant Kaposi's sarcoma. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1997</b> , 8, 130-7	12.3	22
645	Renal transplantation: single or dual for donors aging > or =60 years?. <i>Transplantation</i> , <b>2000</b> , 69, 2000-1	1.5	23
644	Glutathione S-transferase and CYP1A1 gene polymorphisms and non-melanoma skin cancer risk in Italian transplanted patients. <i>Experimental Dermatology</i> , <b>2006</b> , 15, 958-65	3.8	23
643	Renal transplantation: can we reduce calcineurin inhibitor/stop steroids? Evidence based on protocol biopsy findings. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2003</b> , 14, 755-66	12.3	22
642	Automatic generation of glomerular capillary topological organization. <i>Microvascular Research</i> , <b>2001</b> , 62, 346-54	3.6	23
641	Renal prostacyclin biosynthesis is reduced in children with hemolytic-uremic syndrome in the context of systemic platelet activation. <i>American Journal of Kidney Diseases</i> , <b>1992</b> , 20, 144-9	7.2	23
640	Methylprednisolone normalizes superoxide anion production by polymorphs from patients with ANCA-positive vasculitides. <i>Kidney International</i> , <b>1993</b> , 44, 215-20	9.6	24
639	Endothelin and eicosanoid synthesis in cultured mesangial cells. <i>Kidney International</i> , <b>1990</b> , 37, 927-33	9.6	24
638	Superimposed nephritis: a separate entity among glomerular diseases?. <i>American Journal of Kidney Diseases</i> , <b>1986</b> , 7, 205-12	7.2	21

- 637 Prostacyclin (PGI<sub>2</sub>) and bleeding time in uremic patients. *Thrombosis Research*, **1977**, 11, 919-20 7.3 23
- 636 Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). *Kidney International, Supplement*, **1997**, 63, S54-7 24
- 635 Uremic bleeding: closing the circle after 30 years of controversies?. *Blood*, **1999**, 94, 2569-74 2.1 23
- 634 Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. *Kidney International*, **2019**, 96, 555-567 9.6 24
- 633 Spot PC ratio estimates of 24-hour proteinuria are more unreliable in lupus nephritis than in other forms of chronic glomerular disease. *Annals of the Rheumatic Diseases*, **2014**, 73, 475-6 2.3 22
- 632 Thymic microchimerism correlates with the outcome of tolerance-inducing protocols for solid organ transplantation. *Journal of the American Society of Nephrology: JASN*, **2001**, 12, 2815-2826 12.3 21
- 631 Dual blockade of the renin-angiotensin system: the ultimate treatment for renal protection?. *Journal of the American Society of Nephrology: JASN*, **2005**, 16 Suppl 1, S34-8 12.3 23
- 630 Severe early acute humoral rejection resulting in allograft loss in a renal transplant recipient with Campath-1H induction therapy. *Nephrology Dialysis Transplantation*, **2005**, 20, 1741-4 4.1 22
- 629 Deficiency of ADAMTS13 and thrombotic thrombocytopenic purpura. *Blood*, **2002**, 100, 3839-40; author reply 3840-2 2.1 21
- 628 Subcutaneous xenotransplantation of bovine pancreatic islets. *Biomaterials*, **2005**, 26, 5640-7 15.2 22
- 627 17beta-estradiol corrects hemostasis in uremic rats by limiting vascular expression of nitric oxide synthases. *American Journal of Physiology - Renal Physiology*, **2000**, 279, F626-35 4.1 22
- 626 Glomerular perm-selective function. *Kidney International*, **1994**, 45, 398-402 9.6 22
- 625 Renal protective effect of angiotensin-converting enzyme inhibition in aging rats. *American Journal of Medicine*, **1992**, 92, 60S-63S 2.3 23
- 624 Cyclosporine-induced renal dysfunction in experimental animals and humans. *Transplantation Reviews*, **1991**, 5, 63-80 3.3 22
- 623 Bleeding in renal failure: a possible role of vascular prostacyclin (PGI<sub>2</sub>). *Clinical Nephrology*, **1979**, 12, 127-31 1 22
- 622 Comparison of the effects of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade on the evolution of spontaneous glomerular injury in male MWF/Ztm rats. *Experimental Nephrology*, **1996**, 4, 19-25 22
- 621 B7-1 Is Not Induced in Podocytes of Human and Experimental Diabetic Nephropathy. *Journal of the American Society of Nephrology: JASN*, **2016**, 27, 999-1005 12.3 24
- 620 Addition of cyclic angiotensin-(1-7) to angiotensin-converting enzyme inhibitor therapy has a positive add-on effect in experimental diabetic nephropathy. *Kidney International*, **2019**, 96, 906-917 9.6 21



619	Engineered Kidney Tubules for Modeling Patient-Specific Diseases and Drug Discovery. <i>EBioMedicine</i> , <b>2018</b> , 33, 253-268	8.6	21
618	Treatment of Congenital Thrombotic Thrombocytopenic Purpura With Eculizumab. <i>American Journal of Kidney Diseases</i> , <b>2015</b> , 66, 1067-70	7.2	21
617	Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial. <i>PLoS Medicine</i> , <b>2019</b> , 16, e1002777	11.3	21
616	Progression, Remission and Regression of Chronic Renal Diseases. <i>Nephron</i> , <b>2016</b> , 134, 20-4	3.1	21
615	Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis. <i>Transplant International</i> , <b>2017</b> , 30, 1275-1283	2.9	21
614	Both darbepoetin alfa and carbamylated erythropoietin prevent kidney graft dysfunction due to ischemia/reperfusion in rats. <i>Transplantation</i> , <b>2011</b> , 92, 271-9	1.5	21
613	Complement Alternative Pathway Deficiency in Recipients Protects Kidney Allograft From Ischemia/Reperfusion Injury and Alloreactive T Cell Response. <i>American Journal of Transplantation</i> , <b>2017</b> , 17, 2312-2325	8.4	22
612	BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic Syndrome. <i>American Journal of Kidney Diseases</i> , <b>2017</b> , 70, 145-150	7.2	21
611	Immunomodulatory effects of mesenchymal stromal cells in solid organ transplantation. <i>Current Opinion in Organ Transplantation</i> , <b>2010</b> , 15, 731-7	2.4	21
610	Cyclosporine prolongs delayed graft function in kidney transplantation: are rabbit anti-human thymocyte globulins the answer?. <i>Nephron Clinical Practice</i> , <b>2005</b> , 101, c65-71		20
609	Complement factor H and hemolytic uremic syndrome. <i>International Immunopharmacology</i> , <b>2001</b> , 1, 461-87	3.7	21
608	Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. <i>Cochrane Database of Systematic Reviews</i> , <b>2004</b> , CD004293		22
607	Angiotensin-converting enzyme inhibition ameliorates the defect in glomerular size selectivity in hyponatremic hypertensive syndrome. <i>American Journal of Kidney Diseases</i> , <b>1989</b> , 14, 170-7	7.2	21
606	C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , <b>2016</b> , 68, 873-881	7.2	20
605	Prevention programs for chronic kidney disease in low-income countries. <i>Internal and Emergency Medicine</i> , <b>2016</b> , 11, 385-9	3.6	23
604	C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial. <i>American Journal of Kidney Diseases</i> , <b>2019</b> , 74, 224-238	7.2	20
603	Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis. <i>Clinical and Experimental Immunology</i> , <b>2008</b> , 151, 199-209	5.9	19
602	ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease. <i>Current Opinion in Pharmacology</i> , <b>2017</b> , 33, 34-40	4.9	20

601	Screening for chronic kidney disease in emerging countries: feasibility and hurdles. <i>Nephrology Dialysis Transplantation</i> , <b>2009</b> , 24, 1355-8	4.1	33
600	Xenogeneic serum promotes leukocyte-endothelium interaction under flow through two temporally distinct pathways: role of complement and nuclear factor-kappaB. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1999</b> , 10, 2197-207	12.3	19
599	A logistic-regression model provides novel guidelines to maximize the anti-acute rejection properties of cyclosporine with a minimum of toxicity. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1996</b> , 7, 786-91	12.3	18
598	Albumin concentration in the Bowman's capsule: multiphoton microscopy vs micropuncture technique. <i>Kidney International</i> , <b>2007</b> , 72, 1410-1; author reply 1411	9.6	20
597	Renal and metabolic effects of insulin lispro in type 2 diabetic subjects with overt nephropathy. <i>Diabetes Care</i> , <b>2003</b> , 26, 502-9	14.1	20
596	Hyperuricemia in kidney transplantation. <i>Contributions To Nephrology</i> , <b>2005</b> , 147, 124-131	1.5	19
595	Effect of high dose ramipril with or without indomethacin on glomerular selectivity. <i>Kidney International</i> , <b>2002</b> , 62, 1010-9	9.6	20
594	Pathophysiology of disease progression in proteinuric nephropathies. <i>Kidney International</i> , <b>2005</b> , 579-82	9.6	20
593	Acceleration of recovery in acute renal failure: from cellular mechanisms of tubular repair to innovative targeted therapies. <i>Renal Failure</i> , <b>1996</b> , 18, 377-88	2.8	20
592	alpha 1-Antitrypsin therapy in a case of thrombotic thrombocytopenic purpura. <i>Lancet, The</i> , <b>1995</b> , 345, 224-5	36.2	20
591	Role of enhanced glomerular synthesis of thromboxane A2 in progressive kidney disease. <i>Kidney International</i> , <b>1990</b> , 38, 447-58	9.6	21
590	Inhibition of human platelet aggregation by parathyroid hormone. Is cyclic AMP implicated?. <i>American Journal of Nephrology</i> , <b>1985</b> , 5, 243-7	4.4	20
589	Challenges to achieving clinical transplantation tolerance. <i>Journal of Clinical Investigation</i> , <b>2001</b> , 108, 943-8	15.3	21
588	Pathophysiologic implications of proteinuria in a rat model of progressive glomerular injury. <i>Laboratory Investigation</i> , <b>1992</b> , 67, 572-9	5.7	20
587	Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia. <i>Clinical Transplantation</i> , <b>1996</b> , 10, 550-5	3.7	20
586	Endothelin: a mediator of renal disease progression. <i>Journal of Nephrology</i> , <b>1997</b> , 10, 179-83	4.6	20
585	Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial. <i>Lancet Diabetes and Endocrinology, the</i> , <b>2018</b> , 6, 27-40	17.4	19
584	Factor H Competitor Generated by Gene Conversion Events Associates with Atypical Hemolytic Uremic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2018</b> , 29, 240-249	12.3	20

583	Sirolimus to replace calcineurin inhibitors? Too early yet. <i>Lancet, The</i> , <b>2009</b> , 373, 1235-6	36.2	19
582	Effects of angiotensin-converting enzyme inhibition on glomerular capillary wall ultrastructure in MWF/Ztm rats. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1994</b> , 5, 1378-84	12.3	17
581	Recovery of blood mononuclear cell calcineurin activity segregates two populations of renal transplant patients with different sensitivities to cyclosporine inhibition. <i>Transplantation</i> , <b>1996</b> , 61, 1526-31	1.5	20
580	DnIKK2-transfected dendritic cells induce a novel population of inducible nitric oxide synthase-expressing CD4+CD25- cells with tolerogenic properties. <i>Transplantation</i> , <b>2007</b> , 83, 474-84	1.5	19
579	In renal transplantation blood cyclosporine levels soon after surgery act as a major determinant of rejection: insights from the MY.S.S. trial. <i>Kidney International</i> , <b>2004</b> , 65, 1084-90	9.6	19
578	ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. <i>American Journal of Physiology - Renal Physiology</i> , <b>1999</b> , 276, F457-66	4.1	19
577	ACE inhibition prevents renal failure and death in uninephrectomized MWF/Ztm rats. <i>Kidney International</i> , <b>1995</b> , 47, 1319-26	9.6	18
576	Slowing the progression of diabetic nephropathy. <i>New England Journal of Medicine</i> , <b>1993</b> , 329, 1496-7	57.2	19
575	Co-participation of thromboxane A2 and leukotriene C4 and D4 in mediating cyclosporine-induced acute renal failure. <i>Transplantation</i> , <b>1991</b> , 52, 873-8	1.5	19
574	Skin fibroblasts from a patient with Glanzmann's thrombasthenia do not induce fibrin clot retraction. <i>Thrombosis Research</i> , <b>1977</b> , 10, 173-4	7.3	20
573	Constitutive expression of endothelin gene in cultured human mesangial cells and its modulation by transforming growth factor-beta, thrombin, and a thromboxane A2 analogue. <i>Laboratory Investigation</i> , <b>1991</b> , 64, 16-20	5.7	19
572	Liver transplantation for aHUS: still needed in the eculizumab era?. <i>Pediatric Nephrology</i> , <b>2016</b> , 31, 759-68	3.1	18
571	Therapeutic potential of stromal cells of non-renal or renal origin in experimental chronic kidney disease. <i>Stem Cell Research and Therapy</i> , <b>2018</b> , 9, 220	8	18
570	Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy. <i>Pediatric Nephrology</i> , <b>2019</b> , 34, 1311-1323	3.1	18
569	Dual renin-angiotensin system blockade for nephroprotection: still under scrutiny. <i>Nephron</i> , <b>2015</b> , 129, 39-41	3.1	18
568	A previously unrecognized role of C3a in proteinuric progressive nephropathy. <i>Scientific Reports</i> , <b>2016</b> , 6, 28445	4.7	18
567	Old donors for kidney transplantation: how old?. <i>Gerontology</i> , <b>2011</b> , 57, 513-20	5.3	18
566	Baseline characteristics in the Bardoxolone methyl Evaluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal events (BEACON) trial. <i>Nephrology Dialysis Transplantation</i> , <b>2013</b> , 28, 2841-50	4.1	18

565	Intensified inhibition of renin-angiotensin system: a way to improve renal protection?. <i>Current Hypertension Reports</i> , <b>2007</b> , 9, 430-6	4.5	17
564	Primer: strategies for identifying genes involved in renal disease. <i>Nature Clinical Practice Nephrology</i> , <b>2008</b> , 4, 265-76		18
563	Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. <i>Blood</i> , <b>2020</b> , 136, 2103-2117	2.1	19
562	Unrecognized pattern of von Willebrand factor abnormalities in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1999</b> , 10, 1234-41	12.3	18
561	Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies. <i>Journal of Hypertension</i> , <b>2007</b> , 25, 871-6	1.5	18
560	Proteinuria in diabetic nephropathy: treatment and evolution. <i>Current Diabetes Reports</i> , <b>2003</b> , 3, 497-504	5.4	18
559	Research on renal endothelin in proteinuric nephropathies dictates novel strategies to prevent progression. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2001</b> , 10, 1-6	3.4	18
558	Routine renin-angiotensin system blockade in renal transplantation?. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2002</b> , 11, 1-10	3.4	18
557	Lessons from the Di Bella affair. <i>Lancet, The</i> , <b>1999</b> , 353, 1289-90	36.2	18
556	Failure to predict cyclosporine area under the curve using a limited sampling strategy. <i>Kidney International</i> , <b>1993</b> , 44, 436-9	9.6	18
555	Thrombotic microangiopathies. <i>Critical Reviews in Oncology/Hematology</i> , <b>1991</b> , 11, 243-65	6.8	18
554	Prolonged bleeding time and increased vascular prostacyclin in rats with chronic renal failure: effects of conjugated estrogens. <i>Translational Research</i> , <b>1988</b> , 112, 380-6		18
553	Passive Heymann nephritis: evidence that angiotensin-converting enzyme inhibition reduces proteinuria and retards renal structural injury. <i>Experimental Nephrology</i> , <b>1996</b> , 4, 213-21		18
552	Early and late scanning electron microscopy findings in diabetic kidney disease. <i>Scientific Reports</i> , <b>2018</b> , 8, 4909	4.7	17
551	Mitochondrial-dependent Autoimmunity in Membranous Nephropathy of IgG4-related Disease. <i>EBioMedicine</i> , <b>2015</b> , 2, 456-66	8.6	17
550	Nephrology research--the past, present and future. <i>Nature Reviews Nephrology</i> , <b>2015</b> , 11, 677-87	14.3	17
549	Acute kidney injury: more awareness needed, globally. <i>Lancet, The</i> , <b>2015</b> , 386, 1425-7	36.2	17
548	A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: A retrospective observational matched-cohort study. <i>EClinicalMedicine</i> , <b>2021</b> , 37, 100941	11	18

547	Albuminuria as early test for vascular disease. <i>Lancet, The</i> , <b>2005</b> , 365, 556-7	36.2	17
546	Manipulating Sirtuin 3 pathway ameliorates renal damage in experimental diabetes. <i>Scientific Reports</i> , <b>2020</b> , 10, 8418	4.7	17
545	C3a receptor blockade protects podocytes from injury in diabetic nephropathy. <i>JCI Insight</i> , <b>2020</b> , 5,	9.6	18
544	Nitric oxide synthetic capacity in relation to dialysate temperature. <i>Blood Purification</i> , <b>2004</b> , 22, 203-9	2.9	18
543	Independent clinical research in Europe. <i>Lancet, The</i> , <b>2004</b> , 364, 1723-6	36.2	18
542	Nitric oxide/L-arginine in uremia. <i>Mineral and Electrolyte Metabolism</i> , <b>1999</b> , 25, 384-90		17
541	The diagnosis of renal involvement in non-insulin-dependent diabetes mellitus. <i>Current Opinion in Nephrology and Hypertension</i> , <b>1997</b> , 6, 141-5	3.4	17
540	Glucose-induced changes in renal haemodynamics in proteinuric type 1 (insulin-dependent) diabetic patients: inhibition by acetylsalicylic acid infusion. <i>Diabetologia</i> , <b>1993</b> , 36, 622-7	10	19
539	Urinary excretion of platelet activating factor in patients with immune-mediated glomerulonephritis. <i>Kidney International</i> , <b>1993</b> , 43, 426-9	9.6	17
538	Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. <i>Thrombosis and Haemostasis</i> , <b>2009</b> , 101, 233-8	6.8	17
537	Enhanced glomerular thromboxane A2 mediates some pathophysiologic effect of platelet-activating factor in rabbit nephrotoxic nephritis: evidence from biochemical measurements and inhibitor trials. <i>Translational Research</i> , <b>1989</b> , 113, 549-60		18
536	Kidney volume measurement methods for clinical studies on autosomal dominant polycystic kidney disease. <i>PLoS ONE</i> , <b>2017</b> , 12, e0178488	3.6	16
535	Blood Pressure and Metabolic Effects of Acetyl-L-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial. <i>Journal of the Endocrine Society</i> , <b>2018</b> , 2, 420-436	0.3	16
534	The role of B7-1 in proteinuria of glomerular origin. <i>Nature Reviews Nephrology</i> , <b>2018</b> , 14, 589-596	14.3	16
533	Monitoring initial response to Angiotensin-converting enzyme inhibitor-based regimens: an individual patient data meta-analysis from randomized, placebo-controlled trials. <i>Hypertension</i> , <b>2010</b> , 56, 533-9	8	18
532	Enzyme replacement therapy and Fabry nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2010</b> , 5, 371-8	6.7	17
531	Thrice-weekly in-center nocturnal hemodialysis: an effective strategy to optimize chronic dialysis therapy. <i>International Journal of Artificial Organs</i> , <b>2009</b> , 32, 12-9	1.8	16
530	Platelet-activating factor mediates angiotensin II-induced proteinuria in isolated perfused rat kidney. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1997</b> , 8, 1391-8	12.3	16

529	Genetic abnormalities of complement regulators in hemolytic uremic syndrome: how do they affect patient management?. <i>Nature Clinical Practice Nephrology</i> , <b>2005</b> , 1, 2-3		16
528	Modulating the profit motive to meet needs of the less-developed world. <i>Lancet, The</i> , <b>2001</b> , 358, 1638-43	36.2	18
527	Health services: an Italian market. <i>Lancet, The</i> , <b>1996</b> , 348, 167-75	36.2	16
526	Epidemiology of the hemolytic uremic syndrome. <i>New England Journal of Medicine</i> , <b>1991</b> , 324, 1065-6	57.2	16
525	Methylprednisolone dosage effects on peripheral lymphocyte subpopulations and eicosanoid synthesis. <i>Kidney International</i> , <b>1992</b> , 42, 981-90	9.6	16
524	Renal biopsy in patients with acute renal failure and prolonged bleeding time. <i>Lancet, The</i> , <b>1984</b> , 2, 978-9	36.2	16
523	Platelet-activating factor receptor blocking reduces proteinuria and improves survival in lupus autoimmune mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>1991</b> , 258, 601-6	4.5	16
522	Effect of dietary proteins and lipids in patients with membranous nephropathy and nephrotic syndrome. <i>Clinical Nephrology</i> , <b>1991</b> , 35, 237-42	1	16
521	In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. <i>Thrombosis and Haemostasis</i> , <b>2006</b> , 96, 454-64	6.8	17
520	Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 853	8.2	14
519	Mesenchymal stromal cells to control donor-specific memory T cells in solid organ transplantation. <i>Current Opinion in Organ Transplantation</i> , <b>2015</b> , 20, 79-85	2.4	15
518	Eliminating treatable deaths due to acute kidney injury in resource-poor settings. <i>Seminars in Dialysis</i> , <b>2015</b> , 28, 193-7	2.4	14
517	The Role of Angiotensin II in Parietal Epithelial Cell Proliferation and Crescent Formation in Glomerular Diseases. <i>American Journal of Pathology</i> , <b>2017</b> , 187, 2441-2450	5.6	15
516	Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 2329	8.2	16
515	Nephrology in developing countries: the ISN's story. <i>Lancet, The</i> , <b>2014</b> , 383, 1271-1272	36.2	16
514	Which antihypertensive drugs are the most nephroprotective and why?. <i>Expert Opinion on Pharmacotherapy</i> , <b>2010</b> , 11, 2651-63	3.9	15
513	Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism. <i>Pharmacogenetics and Genomics</i> , <b>2009</b> , 19, 695-703	13.9	14
512	Thymus-mediated immune tolerance to renal allograft is donor but not tissue specific. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1991</b> , 2, 1063-71	12.3	14

511	Comparison of different cyclosporine immunoassays to monitor C0 and C2 blood levels from kidney transplant recipients: not simply overestimation. <i>Clinica Chimica Acta</i> , <b>2005</b> , 355, 153-64	3.9	15
510	The future of renoprotection. <i>Kidney International</i> , <b>2005</b> , S95-101	9.6	15
509	Defective platelet aggregation in response to platelet-activating factor in uremia associated with low platelet thromboxane A2 generation. <i>American Journal of Kidney Diseases</i> , <b>1992</b> , 19, 318-25	7.2	15
508	Role of platelet-activating factor in renal immune injury and proteinuria. <i>American Journal of Nephrology</i> , <b>1990</b> , 10 Suppl 1, 98-104	4.4	15
507	Sequence of glomerular changes in experimental endotoxemia: a possible model of hemolytic uremic syndrome. <i>Nephron</i> , <b>1989</b> , 53, 330-7	3.1	15
506	Functional significance of exaggerated renal thromboxane A2 synthesis induced by cyclosporin A. <i>American Journal of Physiology - Renal Physiology</i> , <b>1986</b> , 251, F581-7	4.1	15
505	In vivo platelet activation with in vitro hyperaggregability to arachidonic acid in renal allograft recipients. <i>Kidney International</i> , <b>1983</b> , 23, 506-13	9.6	15
504	Human renal cortex generates prostacyclin-like activity. <i>Thrombosis Research</i> , <b>1978</b> , 12, 363-6	7.3	15
503	Cyclooxygenase products and atrial natriuretic peptide modulate renal response to endothelin. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>1990</b> , 252, 1213-20	4.5	15
502	Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , <b>2019</b> , 73, 309-315	7.2	16
501	Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. <i>American Journal of Kidney Diseases</i> , <b>2013</b> , 61, 238-46	7.2	17
500	Rabbit anti-rat thymocyte immunoglobulin preserves renal function during ischemia/reperfusion injury in rat kidney transplantation. <i>Transplant International</i> , <b>2011</b> , 24, 829-38	2.9	14
499	Targeting the renin angiotensin system in dialysis patients. <i>Seminars in Dialysis</i> , <b>2011</b> , 24, 290-7	2.4	13
498	Non-immune interventions to protect kidney allografts in the long term. <i>Kidney International</i> , <b>2010</b> , S71-5.6		15
497	The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 749-753	6.5	13
496	Rituximab for membranous nephropathy and immune disease: less might be enough. <i>Nature Clinical Practice Nephrology</i> , <b>2009</b> , 5, 76-7		15
495	Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria. <i>Journal of Hypertension</i> , <b>2010</b> , 28, 186-93	1.5	14
494	Preventing end-stage renal disease: the potential impact of screening and intervention in developing countries. <i>Kidney International</i> , <b>2003</b> , 63, 1948-50	9.6	15

493	Prevention of progression and remission/regression strategies for chronic renal diseases: can we do better now than five years ago?. <i>Kidney International</i> , <b>2005</b> , S21-4	9.6	15
492	Acquired transplant tolerance. <i>International Journal of Clinical and Laboratory Research</i> , <b>1997</b> , 27, 165-77		13
491	Recurrent abortion with lupus anticoagulant, and pre-eclampsia: a common final pathway for two different diseases? Case report. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>1986</b> , 93, 194-6	3.5	14
490	The renal toxicity of sustained glomerular protein traffic. <i>Laboratory Investigation</i> , <b>1995</b> , 73, 461-8	5.7	14
489	Renal primordia activate kidney regenerative events in a rat model of progressive renal disease. <i>PLoS ONE</i> , <b>2015</b> , 10, e0120235	3.6	13
488	Sirtuin3 Dysfunction Is the Key Determinant of Skeletal Muscle Insulin Resistance by Angiotensin II. <i>PLoS ONE</i> , <b>2015</b> , 10, e0127172	3.6	13
487	Genetics of Immune-Mediated Glomerular Diseases: Focus on Complement. <i>Seminars in Nephrology</i> , <b>2017</b> , 37, 447-463	4.6	13
486	Safety of Iohexol Administration to Measure Glomerular Filtration Rate in Different Patient Populations: A 25-Year Experience. <i>Nephron</i> , <b>2018</b> , 140, 1-8	3.1	13
485	Renal bioengineering with scaffolds generated from rat and pig kidneys. <i>Nephron Experimental Nephrology</i> , <b>2014</b> , 126, 113		13
484	Mortality landscape in the global burden of diseases, injuries and risk factors study. <i>European Journal of Internal Medicine</i> , <b>2014</b> , 25, 1-5	3.8	14
483	Novel effective drugs for diabetic kidney disease? or not?. <i>Expert Opinion on Emerging Drugs</i> , <b>2014</b> , 19, 571-601	3.5	11
482	Management of chronic kidney disease and its risk factors in eastern Nepal. <i>The Lancet Global Health</i> , <b>2014</b> , 2, e506-e507	12	13
481	Successes and disappointments with clinical islet transplantation. <i>Advances in Experimental Medicine and Biology</i> , <b>2010</b> , 654, 749-69	3.4	13
480	Effect of trandolapril on regression of retinopathy in hypertensive patients with type 2 diabetes: a prespecified analysis of the benedict trial. <i>Journal of Ophthalmology</i> , <b>2010</b> , 2010, 106384	1.9	13
479	Accelerating the Depletion of Circulating Anti-Phospholipase A2 Receptor Antibodies in Patients with Severe Membranous Nephropathy: Preliminary Findings with Double Filtration Plasmapheresis and Ofatumumab. <i>Nephron</i> , <b>2020</b> , 144, 30-35	3.1	13
478	Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. <i>Lancet Oncology</i> , <b>2021</b> , 22, 558-570	20.9	13
477	Blocking cell microtubule assembly inhibits the alloimmune response in vitro and prolongs renal allograft survival by inhibition of Th1 and sparing of Th2 cell function in vivo. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1995</b> , 5, 1418-25	12.3	11
476	Peripheral donor leukocytes prolong survival of rat renal allografts. <i>Kidney International</i> , <b>1999</b> , 56, 1101	9.6	13



475	Nonimmunosuppressive therapy of membranous nephropathy. <i>Seminars in Nephrology</i> , <b>2003</b> , 23, 333-9	4.6	13
474	Renoprotective therapy in patients with nondiabetic nephropathies. <i>Drugs</i> , <b>2001</b> , 61, 733-45	11.6	13
473	Glomerular response to hyperglycemia in human diabetic nephropathy. <i>American Journal of Physiology - Renal Physiology</i> , <b>1990</b> , 259, F545-52	4.1	14
472	Functional implications of decreased renal cortical atrial natriuretic peptide binding in experimental diabetes. <i>Circulation Research</i> , <b>1990</b> , 66, 1453-60	15.3	13
471	Increased urinary excretion of platelet activating factor in mice with lupus nephritis. <i>Life Sciences</i> , <b>1991</b> , 48, 1429-37	6.6	14
470	Differential inhibition by aspirin of platelet thromboxane and renal prostaglandins in the rat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>1989</b> , 248, 334-41	4.5	13
469	Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome. <i>Microorganisms</i> , <b>2019</b> , 7,	4.8	13
468	Effect of ACE inhibition on glomerular permselectivity and tubular albumin concentration in the renal ablation model. <i>American Journal of Physiology - Renal Physiology</i> , <b>2011</b> , 300, F1291-300	4.1	12
467	Discordant phenotype in monozygotic twins with renal coloboma syndrome and a PAX2 mutation. <i>Pediatric Nephrology</i> , <b>2012</b> , 27, 1989-93	3.1	13
466	The diabetic CKD patient--a major cardiovascular challenge. <i>Journal of Renal Care</i> , <b>2010</b> , 36 Suppl 1, 34-46	6.6	13
465	Kidney transplant tolerance associated with remote autologous mesenchymal stromal cell administration. <i>Stem Cells Translational Medicine</i> , <b>2020</b> , 9, 427-432	6.6	12
464	Aldosterone and progression of kidney disease. <i>Therapeutic Advances in Cardiovascular Disease</i> , <b>2009</b> , 3, 133-43	3.3	12
463	Mycophenolate mofetil versus azathioprine in organ transplantation. <i>American Journal of Transplantation</i> , <b>2009</b> , 9, 2856-7	8.4	14
462	Potential protective effects of telmisartan on renal function deterioration. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , <b>2006</b> , 7, 185-91	2.9	11
461	Latest treatment strategies for membranous nephropathy. <i>Expert Opinion on Pharmacotherapy</i> , <b>2007</b> , 8, 3159-71	3.9	13
460	Proteinuria and its consequences in renal disease. <i>Acta Paediatrica, International Journal of Paediatrics</i> , <b>2003</b> , 92, 9-13; discussion 5	3	13
459	Lipid oxidative stress and the anti-inflammatory properties of statins and ACE inhibitors. <i>Journal of Renal Nutrition</i> , <b>2005</b> , 15, 71-6	2.9	12
458	The potential of endothelin antagonism as a therapeutic approach. <i>Expert Opinion on Investigational Drugs</i> , <b>2004</b> , 13, 1419-35	5.7	12

457	Cyclosporine formulation and Kaposi's sarcoma after renal transplantation. <i>Transplantation</i> , <b>2005</b> , 80, 743-8	1.5	12
456	Activation of porcine endothelium in response to xenogeneic serum causes thrombosis independently of platelet activation. <i>Xenotransplantation</i> , <b>2005</b> , 12, 110-20	2.6	13
455	Angiotensin II receptor antagonists and treatment of hypertension and renal disease. <i>Current Opinion in Nephrology and Hypertension</i> , <b>1998</b> , 7, 571-8	3.4	11
454	Relationships among natriuresis, atrial natriuretic peptide and insulin in insulin-dependent diabetes. <i>Kidney International</i> , <b>1992</b> , 41, 813-21	9.6	12
453	High-performance liquid chromatographic determination of iothalamic acid in human plasma and urine. <i>Biomedical Applications</i> , <b>1991</b> , 570, 435-40		12
452	Prostacyclin deficiency in thrombotic microangiopathy. <i>Lancet, The</i> , <b>1981</b> , 2, 1422-3	36.2	12
451	[Abnormal tissue repair in Glanzmann's thrombasthenia]. <i>Lancet, The</i> , <b>1977</b> , 1, 374-5	36.2	13
450	Effect of aspirin and sulindac in rabbit nephrotoxic nephritis. <i>Translational Research</i> , <b>1986</b> , 107, 261-8		12
449	Mechanisms of acquired thymic unresponsiveness to renal allografts. Thymic recognition of immunodominant allo-MHC peptides induces peripheral T cell anergy. <i>Transplantation</i> , <b>1994</b> , 58, 125-32	1.5	12
448	Angiotensin-converting enzyme inhibition and calcium channel blockade both normalize early hyperfiltration in experimental diabetes, but only the former prevents late renal structural damage. <i>Experimental Nephrology</i> , <b>1994</b> , 2, 220-8		12
447	The hemolytic uremic syndrome. <i>Kidney International, Supplement</i> , <b>1998</b> , 66, S54-7		12
446	The renin-angiotensin system in progression, remission and regression of chronic nephropathies. <i>Journal of Hypertension Supplement: Official Journal of the International Society of Hypertension</i> , <b>2002</b> , 20, S45-53		12
445	Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase. <i>Journal of Biological Chemistry</i> , <b>2016</b> , 291, 8214-30	5	11
444	Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial. <i>American Journal of Kidney Diseases</i> , <b>2019</b> , 74, 338-350	7.2	11
443	Mesenchymal stromal cells in kidney transplantation. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2019</b> , 28, 40-46	3.4	11
442	Non-muscle myosins and the podocyte. <i>CKJ: Clinical Kidney Journal</i> , <b>2012</b> , 5, 94-101	4.4	11
441	Spirolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?. <i>Pharmaceuticals</i> , <b>2010</b> , 3, 1-9	5	11
440	Clinical use of computational modeling for surgical planning of arteriovenous fistula for hemodialysis. <i>BMC Medical Informatics and Decision Making</i> , <b>2017</b> , 17, 26	3.5	12

439	Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness. <i>BMJ Case Reports</i> , <b>2020</b> , 13,	0.9	10
438	CTLA4Ig alone or in combination with low-dose cyclosporine fails to reverse acute rejection of renal allograft in the rat. <i>Transplantation</i> , <b>1996</b> , 61, 1320-2	1.5	11
437	Effects of rosuvastatin on glomerular capillary size-selectivity function in rats with renal mass ablation. <i>American Journal of Nephrology</i> , <b>2007</b> , 27, 630-8	4.4	11
436	Combining lisinopril and l-arginine slows disease progression and reduces endothelin-1 in passive Heymann nephritis. <i>Kidney International</i> , <b>2003</b> , 64, 857-63	9.6	11
435	A novel interpretation of the role of von Willebrand factor in thrombotic microangiopathies based on platelet adhesion studies at high shear rate flow. <i>American Journal of Kidney Diseases</i> , <b>2000</b> , 36, 695-702	7.3	11
434	Xenogeneic human serum promotes leukocyte adhesion to porcine endothelium under flow conditions, possibly through the activation of the transcription factor NF-kappa B. <i>Xenotransplantation</i> , <b>1998</b> , 5, 57-60	2.6	11
433	Renal handling of sodium in the nephrotic syndrome. <i>American Journal of Nephrology</i> , <b>1993</b> , 13, 413-21	4.4	11
432	Evidence of the central role of the thymus in the induction of donor-specific unresponsiveness to a renal allograft. <i>Transplantation</i> , <b>1992</b> , 54, 943-5	1.5	10
431	Hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infection in acquired immunodeficiency syndrome [letter]. <i>Blood</i> , <b>1990</b> , 75, 2465-2465	2.1	11
430	Selective inhibition of platelet thromboxane generation with low-dose aspirin does not protect rats with reduced renal mass from the development of progressive disease. <i>American Journal of Pathology</i> , <b>1989</b> , 134, 1027-38	5.6	12
429	Bleeding disorders in uremia: pathophysiology and treatment. <i>Advances in Nephrology From the Necker Hospital</i> , <b>1989</b> , 18, 171-86		11
428	Age-related nephropathy and proteinuria in rats with intact kidneys exposed to diets with different protein content. <i>Laboratory Investigation</i> , <b>1989</b> , 60, 196-204	5.7	11
427	Acute cyclosporine A nephrotoxicity in rats: which role for renin-angiotensin system and glomerular prostaglandins?. <i>Clinical Nephrology</i> , <b>1986</b> , 25 Suppl 1, S83-8	1	11
426	Acute kidney injury in low-income and middle-income countries: no longer a death sentence. <i>The Lancet Global Health</i> , <b>2016</b> , 4, e216-7	12	12
425	Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: A cross-sectional and longitudinal substudy of the ALADIN trial. <i>International Journal of Cardiology</i> , <b>2019</b> , 275, 145-151	3	10
424	Inhibiting angiotensin-converting enzyme promotes renal repair by modulating progenitor cell activation. <i>Pharmacological Research</i> , <b>2016</b> , 108, 16-22	9.9	10
423	Therapeutic Plasma Exchange in Neonates and Infants: Successful Use of a Miniaturized Machine. <i>Blood Purification</i> , <b>2017</b> , 44, 100-105	2.9	10
422	Thrombotic microangiopathies: From animal models to human disease and cure. <i>Contributions To Nephrology</i> , <b>2011</b> , 169, 337-350	1.5	10

421	Prevalence of hypertension and diabetes and coexistence of chronic kidney disease and cardiovascular risk in the population of the republic of moldova. <i>International Journal of Hypertension</i> , <b>2012</b> , 2012, 951734	2.4	10
420	At the peak of COVID-19 age and disease severity but not comorbidities are predictors of mortality: COVID-19 burden in Bergamo, Italy. <i>Panminerva Medica</i> , <b>2021</b> , 63, 51-61	1.6	11
419	Interleukin-1 regulates cytokine gene expression in human mesangial cells through the interleukin-1 receptor type 1. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1992</b> , 2, 1709-15	12.3	10
418	Immunosuppressive therapy abrogates unresponsiveness to renal allograft induced by thymic recognition of donor antigens. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1995</b> , 5, 1618-23	12.3	10
417	Xenotransplantation in the 21st century. <i>Blood Purification</i> , <b>2002</b> , 20, 45-54	2.9	9
416	Optimization of cyclosporine therapy in the Neoral era: abbreviated AUC, single blood sampling?. <i>Transplantation Proceedings</i> , <b>2001</b> , 33, 3117-9	1.1	10
415	Novel mechanism(s) implicated in tubular albumin reabsorption and handling. <i>American Journal of Kidney Diseases</i> , <b>2001</b> , 38, 196-204	7.2	10
414	Losartan in diabetic nephropathy. <i>Expert Review of Cardiovascular Therapy</i> , <b>2004</b> , 2, 473-83	2.4	10
413	Nonviral and viral gene transfer to the kidney in the context of transplantation. <i>Nephron</i> , <b>2000</b> , 85, 307-16	3.1	9
412	Thrombotic microangiopathy. <i>European Journal of Internal Medicine</i> , <b>2000</b> , 11, 135-139	3.8	10
411	Supernatant of endothelial cells exposed to laminar flow inhibits mesangial cell proliferation. <i>American Journal of Physiology - Cell Physiology</i> , <b>1993</b> , 264, C1080-3	5.2	10
410	Low-protein diet and glomerular size-selective function in membranous glomerulopathy. <i>American Journal of Kidney Diseases</i> , <b>1991</b> , 17, 317-22	7.2	11
409	Influence of antacid administrations on aspirin absorption in patients with chronic renal failure on maintenance hemodialysis. <i>American Journal of Kidney Diseases</i> , <b>1988</b> , 11, 338-42	7.2	10
408	Managing hypertension in diabetic patients--focus on trandolapril/verapamil combination. <i>Vascular Health and Risk Management</i> , <b>2007</b> , 3, 453-65	4.3	10
407	17 beta-estradiol is the most active component of the conjugated estrogen mixture active on uremic bleeding by a receptor mechanism. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>1990</b> , 252, 344-8	4.5	10
406	Preliminary results of intrathymic injection of donor cells to prevent acute rejection in human heart transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1995</b> , 6, 1291-4	12.3	9
405	The Cost of Patients with Chronic Kidney Failure Before Dialysis: Results from the IRIDE Observational Study. <i>PharmacoEconomics - Open</i> , <b>2018</b> , 2, 459-467	2.1	9
404	Toward longitudinal studies of hemodynamically induced vessel wall remodeling. <i>International Journal of Artificial Organs</i> , <b>2018</b> , 41, 714-722	1.8	9

403	ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2015</b> , 10, 2002-12	6.7	9
402	A multidrug, antiproteinuric approach to alport syndrome: a ten-year cohort study. <i>Nephron</i> , <b>2015</b> , 130, 13-20	3.1	9
401	Acute Kidney Injury in Poor Countries Should No Longer Be a Death Sentence: The ISN '0 by 25' Project. <i>Annals of Nutrition and Metabolism</i> , <b>2015</b> , 66 Suppl 3, 42-4	4.3	8
400	Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 1177-1190	6.5	9
399	Do attributes of persons with chronic kidney disease differ in low-income and middle-income countries compared with high-income countries? Evidence from population-based data in six countries. <i>BMJ Global Health</i> , <b>2017</b> , 2, e000453	5.4	9
398	An unanticipated role for survivin in organ transplant damage. <i>American Journal of Transplantation</i> , <b>2014</b> , 14, 1046-60	8.4	8
397	Thrombotic microangiopathy: E. coli O104:H4 German outbreak: a missed opportunity. <i>Nature Reviews Nephrology</i> , <b>2012</b> , 8, 558-60	14.3	9
396	Building a network of ADPKD reference centres across Europe: the EuroCYST initiative. <i>Nephrology Dialysis Transplantation</i> , <b>2014</b> , 29 Suppl 4, iv26-32	4.1	10
395	Intermediate volume on computed tomography imaging defines a fibrotic compartment that predicts glomerular filtration rate decline in autosomal dominant polycystic kidney disease patients. <i>American Journal of Pathology</i> , <b>2011</b> , 179, 619-27	5.6	9
394	Investigational drugs for diabetic nephropathy. <i>Expert Opinion on Investigational Drugs</i> , <b>2008</b> , 17, 1487-509	5.9	9
393	Adenoviral-mediated gene transfer restores plasma ADAMTS13 antigen and activity in ADAMTS13 knockout mice. <i>Gene Therapy</i> , <b>2009</b> , 16, 1373-9	3.8	9
392	Renal metabolism and urinary excretion of platelet-activating factor in the rat.. <i>Journal of Biological Chemistry</i> , <b>1990</b> , 265, 19414-19419	5	7
391	Alteration of thyroid hormone signaling triggers the diabetes-induced pathological growth, remodeling, and dedifferentiation of podocytes. <i>JCI Insight</i> , <b>2019</b> , 4,	9.6	9
390	Inhibition of TGF-beta expression: a novel role for thiazolidinediones to implement renoprotection in diabetes. <i>Kidney International</i> , <b>2007</b> , 72, 1419-21	9.6	9
389	Favorable effect of cotransfection with TGF-beta and CTLA4Ig of the donor kidney on allograft survival. <i>American Journal of Nephrology</i> , <b>2004</b> , 24, 275-83	4.4	10
388	ACE inhibitors and AT1 receptor antagonists: is two better than one?. <i>Kidney International</i> , <b>2002</b> , 61, 1545-7	9.6	9
387	The renoprotective potential of endothelin receptor antagonists. <i>Expert Opinion on Therapeutic Patents</i> , <b>1997</b> , 7, 139-149	6.5	9
386	Role of endothelin in the development of glomerulosclerosis. <i>Kidney and Blood Pressure Research</i> , <b>1996</b> , 19, 182-3	2.9	9

385	Glomerulonephritis. <i>Current Opinion in Nephrology and Hypertension</i> , <b>1993</b> , 2, 465-74	3.4	9
384	Prevalence and significance of hypertension in systemic lupus erythematosus. <i>American Journal of Kidney Diseases</i> , <b>1993</b> , 21, 58-60	7.2	8
383	What is the basis for the use of steroids in the treatment of idiopathic membranous nephropathy?. <i>Nephron</i> , <b>1987</b> , 45, 1-6	3.1	9
382	Studies by conventional and low denaturing isoelectric focusing on albumin microheterogeneity under normal conditions and in experimental nephrosis. <i>Electrophoresis</i> , <b>1987</b> , 8, 215-220	3.4	9
381	Renal metabolism and urinary excretion of platelet-activating factor in the rat. <i>Journal of Biological Chemistry</i> , <b>1990</b> , 265, 19414-9	5	9
380	Nitric oxide/endothelin balance after nephron reduction. <i>Kidney International, Supplement</i> , <b>1998</b> , 65, S63-7		9
379	Whole-blood calcineurin activity is not predicted by cyclosporine blood concentration in renal transplant recipients. <i>Clinical Chemistry</i> , <b>2001</b> , 47, 1679-87	5.3	9
378	Effect of Timing and Complement Receptor Antagonism on Intragraft Recruitment and Protolerogenic Effects of Mesenchymal Stromal Cells in Murine Kidney Transplantation. <i>Transplantation</i> , <b>2019</b> , 103, 1121-1130	1.5	8
377	Perioperative Minimal Induction Therapy: A Further Step toward More Effective Immunosuppression in Transplantation. <i>Journal of Transplantation</i> , <b>2012</b> , 2012, 426042	2.3	8
376	Embryonic stem cells, derived either after in vitro fertilization or nuclear transfer, prolong survival of semiallogeneic heart transplants. <i>Journal of Immunology</i> , <b>2011</b> , 186, 4164-74	5.2	8
375	Colchicine allows prolonged survival of highly reactive renal allograft in the rat. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1993</b> , 4, 1294-9	12.3	8
374	The KIDSTEM European Research Training Network: Developing a Stem Cell Based Therapy to Replace Nephrons Lost through Reflux Nephropathy. <i>Organogenesis</i> , <b>2007</b> , 3, 2-5	1.6	8
373	Emerging drugs for diabetic nephropathy. <i>Expert Opinion on Emerging Drugs</i> , <b>2005</b> , 10, 747-71	3.5	8
372	Blood cyclosporine level soon after kidney transplantation is a major determinant of rejection: insights from the Mycophenolate Steroid-Sparing Trial. <i>Transplantation Proceedings</i> , <b>2005</b> , 37, 2037-40	1.1	8
371	Fighting renal diseases in poor countries: building a global fund with the help of the pharmaceutical industry. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2004</b> , 15, 704-7	12.3	10
370	One or two marginal organs for kidney transplantation?. <i>Transplantation Proceedings</i> , <b>2002</b> , 34, 3091-6	1.1	8
369	A unifying hypothesis for renal scarring linking protein trafficking to the different mediators of injury. <i>Nephrology Dialysis Transplantation</i> , <b>2000</b> , 15 Suppl 6, 58-60	4.1	8
368	Pretreatment blood pressure reliably predicts progression of chronic nephropathies. GISEN Group. <i>Kidney International</i> , <b>2000</b> , 58, 2093-101	9.6	8

367	Renoprotective effect of ACE inhibitors: dissecting the molecular clues and expanding the blood pressure goal. <i>American Journal of Kidney Diseases</i> , <b>1999</b> , 34, 951-4	7.2	9
366	Preliminary report: renal thromboxane A2 synthesis in children with frequent relapsing nephrotic syndrome. <i>Lancet, The</i> , <b>1990</b> , 336, 533-4	36.2	9
365	Morphometrical analysis of glomerular changes induced by cyclosporine in the rat. <i>American Journal of Kidney Diseases</i> , <b>1991</b> , 17, 537-43	7.2	8
364	Hyperparathyroidism does not influence the abnormal primary haemostasis in patients with chronic renal failure. <i>Nephrology Dialysis Transplantation</i> , <b>1989</b> , 4, 971-4	4.1	8
363	Abnormalities of arachidonate metabolism in experimental ciclosporin nephrotoxicity. <i>American Journal of Nephrology</i> , <b>1989</b> , 9 Suppl 1, 72-7	4.4	8
362	The lupus anticoagulant. <i>Experimental Biology and Medicine</i> , <b>1984</b> , 176, 337-41	3.6	8
361	Heparin for Hemodialysis: Practical Guidelines for Administration and Monitoring. <i>International Journal of Artificial Organs</i> , <b>1984</b> , 7, 269-274	1.8	8
360	Factor VIII--related protein on vascular intima of patients with chronic renal failure and prolonged bleeding times. <i>The BMJ</i> , <b>1978</b> , 1, 70-2		8
359	Abnormal platelet function in haemodialysed patients: current concepts. <i>International Journal of Artificial Organs</i> , <b>1979</b> , 2, 109-12	1.8	8
358	Development of a mass spectrometric method to quantitate platelet activating factor in mouse urine. <i>Journal of Lipid Research</i> , <b>1989</b> , 30, 1977-81	6	8
357	Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes. <i>Frontiers in Genetics</i> , <b>2019</b> , 10, 681	4.4	6
356	Prognosis and determinants of serum PTH changes over time in 1-5 CKD stage patients followed in tertiary care. <i>PLoS ONE</i> , <b>2018</b> , 13, e0202417	3.6	7
355	Urinary proteome signature of Renal Cysts and Diabetes syndrome in children. <i>Scientific Reports</i> , <b>2019</b> , 9, 2225	4.7	8
354	Determining the Optimal Protocol for Measuring an Albuminuria Class Transition in Clinical Trials in Diabetic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2016</b> , 27, 3405-3412	12.3	7
353	Advances in the pathology of glomerular diseases. <i>Contributions To Nephrology</i> , <b>2013</b> , 181, 12-21	1.5	7
352	Idiopathic membranous nephropathy: back to the future?. <i>Lancet, The</i> , <b>2013</b> , 381, 706-8	36.2	7
351	Chronic kidney disease in sub-Saharan Africa: a public health priority. <i>The Lancet Global Health</i> , <b>2014</b> , 2, e124-5	12	7
350	The European Rare Kidney Disease Registry (ERKReg): objectives, design and initial results. <i>Orphanet Journal of Rare Diseases</i> , <b>2021</b> , 16, 251	4.1	7

349	Pharmacokinetic/pharmacodynamic drug interaction between rosiglitazone and mycophenolate mofetil in kidney transplantation: a case report. <i>Transplantation</i> , <b>2008</b> , 85, 921-2	1.5	7
348	Limited sampling strategies for the estimation of sirolimus daily exposure in kidney transplant recipients on a calcineurin inhibitor-free regimen. <i>Journal of Clinical Pharmacology</i> , <b>2009</b> , 49, 773-81	2.8	7
347	Development of a mass spectrometric method to quantitate platelet activating factor in mouse urine.. <i>Journal of Lipid Research</i> , <b>1989</b> , 30, 1977-1981	6	6
346	Immunomodulation by intrathymic injection of donor leukocytes in rhesus monkeys. <i>Transplantation</i> , <b>2001</b> , 72, 1432-6	1.5	7
345	Impediments to successful gene transfer to the kidney in the context of transplantation and how to overcome them. <i>Kidney International</i> , <b>2002</b> , 61, S115-9	9.6	7
344	Hyperhomocysteinemia and increased risk of retinopathy: a cross-sectional, case-control study in patients with type 2 diabetes. <i>Diabetes Care</i> , <b>2002</b> , 25, 2361	14.1	5
343	Effect of cigarette smoking on renal function and vascular endothelium. <i>Contributions To Nephrology</i> , <b>2000</b> , 130, 45-52	1.5	7
342	Transplant tolerance: will genes protect the graft?. <i>Lancet, The</i> , <b>1998</b> , 351, 1749-51	36.2	7
341	Transplant tolerance: progress and challenges. <i>Journal of Nephrology</i> , <b>2010</b> , 23, 263-70	4.6	7
340	Thrombospondin induces glomerular mesangial cell adhesion and migration. <i>Laboratory Investigation</i> , <b>1992</b> , 67, 566-71	5.7	7
339	Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency. <i>Journal of Nephrology</i> , <b>2002</b> , 15, 428-30	4.6	7
338	Need for chronic kidney disease prevention programs in disadvantaged populations. <i>Clinical Nephrology</i> , <b>2015</b> , 83, 42-8	1	7
337	A preclinical overview of emerging therapeutic targets for glomerular diseases. <i>Expert Opinion on Therapeutic Targets</i> , <b>2019</b> , 23, 593-606	6.2	6
336	Achieving remission of proteinuria in childhood CKD. <i>Pediatric Nephrology</i> , <b>2017</b> , 32, 321-330	3.1	6
335	Oral acetyl-L-carnitine therapy and insulin resistance. <i>Hypertension</i> , <b>2010</b> , 55, e26	8	6
334	Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Drugs in R and D</i> , <b>2017</b> , 17, 441-448 <sup>3,3</sup>		6
333	Recognition and management of community-acquired acute kidney injury in low-resource settings in the ISN Oby25 trial: A multi-country feasibility study. <i>PLoS Medicine</i> , <b>2021</b> , 18, e1003408	11.3	6
332	Third-party bone marrow-derived mesenchymal stromal cell infusion before liver transplantation: A randomized controlled trial. <i>American Journal of Transplantation</i> , <b>2021</b> , 21, 2795-2809	8.4	6



331	Bergamo and Covid-19: How the Dark Can Turn to Light. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 609440	4.7	6
330	Treating the kidney to cure the heart. <i>Kidney International</i> , <b>2008</b> , S2-3	9.6	6
329	Propionyl-L-carnitine prevents early graft dysfunction in allogeneic rat kidney transplantation. <i>Kidney International</i> , <b>2008</b> , 74, 1420-8	9.6	6
328	Intensified inhibition of renin-angiotensin system: a way to improve renal protection?. <i>Current Hypertension Reports</i> , <b>2009</b> , 11, 118-24	4.5	6
327	Complement factor h gene abnormalities in haemolytic uraemic syndrome: from point mutations to hybrid gene. <i>PLoS Medicine</i> , <b>2006</b> , 3, e432	11.3	6
326	Renoprotection: clues from knockout models of rare diseases. <i>Kidney International</i> , <b>2003</b> , 63, 764-6	9.6	6
325	Predicting end-stage renal disease: Bayesian perspective of information transfer in the clinical decision-making process at the individual level. <i>Kidney International</i> , <b>2003</b> , 63, 1924-33	9.6	7
324	Prognosis of diabetic nephropathy: how to improve the outcome. <i>Diabetes Research and Clinical Practice</i> , <b>1998</b> , 39 Suppl, S49-53	7.2	6
323	Identification of a novel gene--SSK1--in human endothelial cells exposed to shear stress. <i>Biochemical and Biophysical Research Communications</i> , <b>1998</b> , 246, 881-7	3.3	6
322	Recent developments in the management of membranous nephropathy. <i>Expert Opinion on Investigational Drugs</i> , <b>1997</b> , 6, 521-32	5.7	6
321	Abnormalities in arachidonic acid metabolites in nephrotoxic glomerular injury. <i>Toxicology Letters</i> , <b>1989</b> , 46, 65-75	4.2	6
320	Platelet-activating factor alters glomerular barrier size selectivity for macromolecules in rats. <i>American Journal of Physiology - Renal Physiology</i> , <b>1991</b> , 261, F85-90	4.1	6
319	Glomerular size selectivity in nephrotic rats exposed to diets with different protein content. <i>American Journal of Physiology - Renal Physiology</i> , <b>1987</b> , 253, F318-27	4.1	6
318	Metabolism of arachidonic acid in isolated glomeruli from pig kidney. <i>Lipids and Lipid Metabolism</i> , <b>1988</b> , 961, 110-21		7
317	Platelet and vascular prostaglandins in uraemia, thrombotic microangiopathy and pre-eclampsia. <i>Philosophical Transactions of the Royal Society of London Series B, Biological Sciences</i> , <b>1981</b> , 294, 339-42		6
316	Does aspirin precipitate major gastrointestinal bleeding in patients on haemodialysis?. <i>Lancet, The</i> , <b>1977</b> , 2, 359-60	36.2	6
315	Myasthenia gravis, thrombocytopenia and HLA antigens. <i>Annals of Internal Medicine</i> , <b>1977</b> , 87, 250-1	7.8	6
314	Intermittent heparin treatment does not induce hypercoagulability in haemodialysed patients. <i>Journal of Clinical Pathology</i> , <b>1980</b> , 33, 631-4	3.8	6

313	FK 506 does not affect the glomerular filtration rate and renal plasma flow in the rat. <i>Transplantation Proceedings</i> , <b>1991</b> , 23, 3123-5	1.1	6
312	Low levels of the anticoagulant activity of protein C in patients with chronic renal insufficiency: an inhibitor of protein C is present in uremic plasma. <i>Thrombosis and Haemostasis</i> , <b>1991</b> , 66, 420-5	6.8	6
311	Effect of platelet-activating factor and its specific receptor antagonist on glomerular permeability to proteins in isolated perfused rat kidney. <i>Laboratory Investigation</i> , <b>1988</b> , 58, 163-71	5.7	6
310	Coagulation defects in uremia. <i>Kidney International, Supplement</i> , <b>1988</b> , 24, S13-7		6
309	Prostacyclin and renal diseases. <i>Clinical Nephrology</i> , <b>1982</b> , 18, 111-9	1	6
308	Endothelin in the progressive renal disease of glomerulopathies. <i>Mineral and Electrolyte Metabolism</i> , <b>1995</b> , 21, 283-91		6
307	How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?. <i>Clinical Transplantation</i> , <b>1998</b> , 12, 379-90	3.7	6
306	Increased fragmentation of von Willebrand factor, due to abnormal cleavage of the subunit, parallels disease activity in recurrent hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and discloses predisposition in families. The Italian Registry of Familial and Recurrent HUS/TTP. <i>Blood</i> , <b>1999</b> , 94, 610-20	2.1	6
305	Pharmacokinetic study of the new cyclosporine-A formulation (Neoral) in adult allogeneic bone marrow transplant recipients. <i>Haematologica</i> , <b>2001</b> , 86, 311-5	6.4	6
304	The role of the endothelium in hemolytic uremic syndrome. <i>Journal of Nephrology</i> , <b>2001</b> , 14 Suppl 4, S58-62	4.6	6
303	Disaster medicine and response: Optimizing life-saving potential. <i>American Journal of Disaster Medicine</i> , <b>2018</b> , 13, 253-264	0.6	6
302	Epidemiology of End-Stage Renal Failure <b>2017</b> , 5-11		5
301	Invited letter in response to: "Is the kidney donor profile index (KDPI) universal or UNOS-specific?". <i>American Journal of Transplantation</i> , <b>2018</b> , 18, 1033-1034	8.4	5
300	Recent advances in immunosuppression and acquired immune tolerance in renal transplants. <i>American Journal of Physiology - Renal Physiology</i> , <b>2016</b> , 310, F446-53	4.1	5
299	Terminal complement effectors in atypical hemolytic uremic syndrome: C5a, C5b-9, or a bit of both?. <i>Kidney International</i> , <b>2019</b> , 96, 13-15	9.6	5
298	More about Factor H Autoantibodies in Membranous Nephropathy. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1590-1592	57.2	5
297	Another Piece of the Puzzle of Podocyte B7-1 Expression: Lupus Nephritis. <i>Nephron</i> , <b>2016</b> , 133, 129-38	3.1	7
296	Low-dose rituximab for posttransplant recurrent membranous nephropathy. <i>American Journal of Transplantation</i> , <b>2010</b> , 10, 1336	8.4	5

295	Cell transplantation for diabetes therapy [Authors' reply. <i>Lancet, The</i> , <b>2008</b> , 372, 29-30	36.2	5
294	Allograft rejection: acute and chronic studies. <i>Contributions To Nephrology</i> , <b>2008</b> , 159, 122-134	1.5	5
293	Islet transplantation: need for a time-out?. <i>Nature Clinical Practice Nephrology</i> , <b>2008</b> , 4, 660-1		5
292	Atypical hemolytic uremic syndrome associated with a factor B genetic variant and fluid-phase complement activation: an exception to the rule?. <i>Kidney International</i> , <b>2020</b> , 98, 1084-1087	9.6	5
291	ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type2 Diabetic Patients With CKD. <i>American Journal of Kidney Diseases</i> , <b>2017</b> , 70, 522-531	7.2	6
290	Reply to the Comment by Dr. Cure on "Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade". <i>Nephron</i> , <b>2020</b> , 144, 253-254	3.1	5
289	Novel therapies of lupus nephritis. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2008</b> , 17, 156-61	3.4	5
288	Effect of seliciclib (CYC202, R-roscovitine) on lymphocyte alloreactivity and acute kidney allograft rejection in rat. <i>Transplantation</i> , <b>2008</b> , 85, 1476-82	1.5	5
287	A recurrent question from a primary care physician: How should I treat my COVID-19 patients at home?. <i>Clinical and Medical Investigations</i> , <b>2020</b> , 5,	1.3	5
286	COVID-19 pandemic and total mortality in the first six months of 2020 in Italy. <i>Medicina Del Lavoro</i> , <b>2020</b> , 111, 351-353	1.8	6
285	Fluid Shear Stress Modulates von Willebrand Factor Release From Human Vascular Endothelium. <i>Blood</i> , <b>1997</b> , 90, 1558-1564	2.1	5
284	Complement hyperactivation may cause atypical haemolytic uraemic syndrome--gain-of-function mutations in factor B. <i>Nephrology Dialysis Transplantation</i> , <b>2007</b> , 22, 2452-4	4.1	5
283	Therapeutic use of HMG-CoA reductase inhibitors: current practice and future perspectives. <i>Expert Opinion on Therapeutic Patents</i> , <b>2004</b> , 14, 1553-1566	6.5	5
282	Autologous stem cell and kidney transplantation for primary amyloidosis associated with ESRD: which should come first?. <i>American Journal of Transplantation</i> , <b>2005</b> , 5, 1585-6	8.4	5
281	Organs for transplantation. <i>New England Journal of Medicine</i> , <b>2000</b> , 343, 1730-1; author reply 1732	57.2	6
280	IgA nephropathy: a stem cell disease?. <i>Kidney International</i> , <b>1999</b> , 56, 1964-6	9.6	4
279	Are HUS and TTP genetically determined?. <i>Kidney International</i> , <b>1998</b> , 53, 1085-6	9.6	5
278	Idiopathic membranous nephropathy. <i>Lancet, The</i> , <b>1993</b> , 342, 1277-1280	36.2	5

277	Treatment of idiopathic membranous glomerulopathy. <i>Current Opinion in Nephrology and Hypertension</i> , <b>1994</b> , 3, 155-63	3.4	5
276	Low-dose aspirin and bleeding in uremia. <i>American Journal of Hematology</i> , <b>1993</b> , 42, 235-6	6.9	4
275	Metabolism of thromboxane B2 in the isolated perfused rat kidney: mass spectrometric identification of urinary products. <i>Lipids and Lipid Metabolism</i> , <b>1989</b> , 1006, 167-72		5
274	Oral zeranol shortens the prolonged bleeding time of uremic rats. <i>Kidney International</i> , <b>1990</b> , 38, 96-100	9.6	5
273	C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19. <i>Blood Advances</i> , <b>2021</b> ,	7.5	5
272	Renal handling of aspirin in the rat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>1989</b> , 251, 295-304	4.5	5
271	Eicosanoids and platelet activating factor as possible mediators of injury in experimental nephropathies. <i>Advances in Experimental Medicine and Biology</i> , <b>1989</b> , 259, 221-47	3.4	5
270	Steroids and Adriamycin nephrosis. <i>Applied Pathology</i> , <b>1984</b> , 2, 32-8		5
269	The possible role of endothelin in the process of progressive renal deterioration in experimental and human glomerulopathies. <i>Seminars in Nephrology</i> , <b>1993</b> , 13, 137-43	4.6	5
268	International Society of Nephrology's perspective on the emergence of chronic kidney diseases of unknown/undetermined etiology. <i>MEDICC Review</i> , <b>2014</b> , 16, 75-6	1	5
267	ADAMTS13 Deficiency Shortens the Life Span of Mice With Experimental Diabetes. <i>Diabetes</i> , <b>2018</b> , 67, 2069-2083	0.7	4
266	Low-dose RATG with or without basiliximab in renal transplantation: a matched-cohort observational study. <i>American Journal of Nephrology</i> , <b>2015</b> , 41, 16-27	4.4	4
265	RAS blockade: Nephroprotection by dual RAS blockade--a welcome back. <i>Nature Reviews Nephrology</i> , <b>2015</b> , 11, 507-8	14.3	3
264	Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. <i>American Journal of Nephrology</i> , <b>2017</b> , 46, 488-497	4.4	5
263	Data on the assessment of LV mechanics by speckle tracking echocardiography in ADPKD patients. <i>Data in Brief</i> , <b>2018</b> , 21, 2075-2081	1.2	4
262	Renin-angiotensin system: Meta-analyses can misdirect decisions on treatment. <i>Nature Reviews Nephrology</i> , <b>2013</b> , 9, 311-2	14.3	4
261	Ethical disputes still beset Italian medicine 150 years after Count Cavour's death. <i>Lancet, The</i> , <b>2012</b> , 379, 1068-73	36.2	5
260	Thrombotic Microangiopathies, Including Hemolytic Uremic Syndrome <b>2010</b> , 344-355		2

259	Does remission of renal disease associated with antihypertensive treatment exist?. <i>Current Hypertension Reports</i> , <b>2007</b> , 9, 160-5	4.5	4
258	Candesartan and renal protection: more than blocking angiotensin type 1 receptor?. <i>Kidney International</i> , <b>2008</b> , 74, 1112-4	9.6	4
257	Autotaxin Inhibitor Protects from Chronic Allograft Injury in Rat Kidney Allotransplantation. <i>Nephron</i> , <b>2020</b> , 144, 38-48	3.1	4
256	The establishment and validation of novel therapeutic targets to retard progression of chronic kidney disease. <i>Kidney International Supplements</i> , <b>2017</b> , 7, 130-137	6.2	4
255	Mycophenolate mofetil versus azathioprine in kidney transplant recipients on steroid-free, low-dose cyclosporine immunosuppression (ATHENA): A pragmatic randomized trial. <i>PLoS Medicine</i> , <b>2021</b> , 18, e1003668	11.3	4
254	A recurrent question from a primary care physician: How should I treat my COVID-19 patients at home? An update. <i>Clinical and Medical Investigations</i> , <b>2020</b> , 5,	1.3	5
253	Role of ultrastructural determinants of glomerular permeability in ultrafiltration function loss. <i>JCI Insight</i> , <b>2020</b> , 5,	9.6	5
252	Misleading meta-analysis: a need to look beyond the headlines. <i>Diabetic Medicine</i> , <b>2007</b> , 24, 587-91	3.4	5
251	Chronic nephropathies: individual risk for progression to end-stage renal failure as predicted by an integrated probabilistic model. <i>Nephron Clinical Practice</i> , <b>2003</b> , 95, c47-59		4
250	Genetics of rare diseases of the kidney: learning from mouse models. <i>Cytogenetic and Genome Research</i> , <b>2004</b> , 105, 479-84	1.7	5
249	Tacrolimus and ciclosporin microemulsion in renal transplantation. <i>Lancet, The</i> , <b>2002</b> , 360, 799-800, author reply 800-1	36.2	4
248	Conflict of interest as seen from a researcher's perspective. <i>Science and Engineering Ethics</i> , <b>2002</b> , 8, 337-42		4
247	Two-hour post-dose cyclosporine monitoring does not fit all in kidney transplantation. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2005</b> , 2, 95-105		4
246	Hemolytic uremic syndrome: past and present. <i>American Journal of Kidney Diseases</i> , <b>2000</b> , 36, LIV-VI	7.2	4
245	Inflammation and glomerular injury. <i>Seminars in Immunopathology</i> , <b>1994</b> , 16, 39-51		4
244	The role of eicosanoids in the pathogenesis of hemolytic uremic syndrome. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , <b>1994</b> , 51, 75-9	2.7	4
243	Turnour necrosis factor stimulates endothelin-1 gene expression in cultured bovine endothelial cells. <i>Mediators of Inflammation</i> , <b>1992</b> , 1, 263-6	4.1	4
242	Renin-angiotensin system and glomerular prostaglandins in early nephrotoxicity of ciclosporin. <i>Contributions To Nephrology</i> , <b>1986</b> , 51, 120-5	1.5	4

241	Steroids and cytotoxic drugs in the treatment of membranous glomerulopathy. <i>Nephron</i> , <b>1988</b> , 50, 263-4.	3.1	4
240	Pathogenesis of Preeclampsia <b>1986</b> , 13-33		4
239	Pathogenesis and treatment of thrombotic microangiopathy. <i>Kidney International, Supplement</i> , <b>1997</b> , 58, S97-101		4
238	Vascular access-related thrombotic complications: research hypotheses and therapeutic strategies. <i>Journal of Nephrology</i> , <b>2006</b> , 19, 280-5	4.6	4
237	Recellularization of Kidney Scaffold With Stem Cells <b>2017</b> , 877-886		3
236	Reply to 'Strengths and limitations of estimated and measured GFR'. <i>Nature Reviews Nephrology</i> , <b>2019</b> , 15, 785-786	14.3	3
235	CRISPR-Cas9-Mediated Correction of the G189R-PAX2 Mutation in Induced Pluripotent Stem Cells from a Patient with Focal Segmental Glomerulosclerosis. <i>CRISPR Journal</i> , <b>2019</b> , 2, 108-120	2.4	3
234	Should We Still Believe in Randomized Controlled Trials in Nephrology?. <i>Nephron</i> , <b>2017</b> , 136, 281-286	3.1	4
233	High serum cholesterol: a missed risk factor for chronic kidney disease mortality. <i>Lancet Diabetes and Endocrinology</i> , <b>2014</b> , 2, 613-4	17.4	3
232	Dual RAS blockade-controversy resolved. <i>Nature Reviews Nephrology</i> , <b>2013</b> , 9, 640	14.3	3
231	Comment on: Robertson (2010) Islet transplantation a decade later and strategies for filling a half-full glass. <i>Diabetes</i> ;59:1285-1291. <i>Diabetes</i> , <b>2010</b> , 59, e13; author reply e14	0.7	3
230	Lymphocyte depletion for kidney transplantation: back to the past?. <i>Nature Clinical Practice Nephrology</i> , <b>2008</b> , 4, 534-5		3
229	Update on mesenchymal stromal cell studies in organ transplant recipients. <i>Current Opinion in Organ Transplantation</i> , <b>2020</b> , 25, 27-34	2.4	3
228	Molecular Studies and an Complement Assay on Endothelium Highlight the Genetic Complexity of Atypical Hemolytic Uremic Syndrome: The Case of a Pedigree With a Null CD46 Variant. <i>Frontiers in Medicine</i> , <b>2020</b> , 7, 579418	4.7	3
227	Transplantation-Induced Ischemia-Reperfusion Injury Modulates Antigen Presentation by Donor Renal CD11cF4/80 Macrophages through IL-1R8 Regulation. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2020</b> , 31, 517-531	12.3	3
226	New biologics in the treatment of rare glomerular diseases of childhood. <i>Current Opinion in Pharmacology</i> , <b>2017</b> , 33, 27-33	4.9	3
225	The impact of COVID-19 on total mortality in Italy up to November 2020. <i>Panminerva Medica</i> , <b>2021</b> ,	1.6	1
224	Genetic testing in the diagnosis of chronic kidney disease: recommendations for clinical practice. <i>Nephrology Dialysis Transplantation</i> , <b>2021</b> ,	4.1	3

223	Excess mortality in Italy in 2020 by sex and age groups accounting for demographic changes and temporal trends in mortality. <i>Panminerva Medica</i> , <b>2021</b> ,	1.6	3
222	Omega-3 polyunsaturated fatty acids affect sirolimus exposure in kidney transplant recipients on calcineurin inhibitor-free regimen. <i>Transplantation</i> , <b>2010</b> , 89, 126-7	1.5	3
221	ADP, Ristocetin, Bovine Factor VIII and Thrombasthenic Platelets. <i>Thrombosis and Haemostasis</i> , <b>1976</b> , 36, 286-288	6.8	3
220	Role of thymic- and graft-dependent mechanisms in tolerance induction to rat kidney transplant by donor PBMC infusion. <i>Kidney International</i> , <b>2007</b> , 71, 1132-41	9.6	3
219	Kidney failure stabilizes after an increase over 2 decades. <i>Journal of Renal Care</i> , <b>2007</b> , 33, 100-4	1.6	3
218	Let's assume that hepatitis C reduces the cardiovascular risk in dialysis patients: are there practical implications?. <i>Journal of Hepatology</i> , <b>2006</b> , 44, 837-8	3.1	3
217	Mycophenolic acid formulation affects cyclosporine pharmacokinetics in stable kidney transplant recipients. <i>Therapeutic Drug Monitoring</i> , <b>2006</b> , 28, 643-9	3.1	3
216	Familial and recurrent forms of hemolytic uremic syndrome/thrombotic thrombocytopenic purpura. <i>Contributions To Nephrology</i> , <b>2001</b> , 136, 125-39	1.5	3
215	Section Review Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: New antirejection drugs. <i>Expert Opinion on Therapeutic Patents</i> , <b>1996</b> , 6, 871-891	6.5	3
214	Interleukin-1 and glomerular mesangial cells. <i>Kidney and Blood Pressure Research</i> , <b>1993</b> , 16, 89-92	2.9	3
213	Interleukin-6 stimulates gene expression of extracellular matrix components in bovine mesangial cells in culture. <i>Mediators of Inflammation</i> , <b>1993</b> , 2, 429-33	4.1	3
212	Induction of unresponsiveness via intrathymic inoculation. <i>Lancet, The</i> , <b>1991</b> , 338, 450	36.2	3
211	Effects of tertatolol on renal function in the isolated perfused rat kidney. <i>American Journal of Hypertension</i> , <b>1989</b> , 2, 223S-227S	2.1	3
210	Stagnations and regressions in the treatment of primary glomerulonephritis. <i>Lancet, The</i> , <b>1983</b> , 2, 90-2	36.2	3
209	Asphyxia in Goodpasture's syndrome: Early treatment by immunosuppression and plasma exchange. <i>Lancet, The</i> , <b>1978</b> , 1, 552	36.2	3
208	Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study.. <i>PLoS ONE</i> , <b>2021</b> , 16, e0261113	3.6	3
207	Excess total mortality in 2021 in Italy was about one third of that observed in 2020.. <i>Medicina Del Lavoro</i> , <b>2021</b> , 112, 414-421	1.8	3
206	The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics. <i>American Journal of Nephrology</i> , <b>2021</b> , 52, 827-836	4.4	3

205	Tertatolol ameliorates renal function in rats with chronic renal failure. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>1988</b> , 246, 287-93	4.5	3
204	The hemolytic uremic syndrome. <i>International Journal of Artificial Organs</i> , <b>1985</b> , 8, 171-4	1.8	3
203	Studies of privileged sites and organ transplantation. <i>Experimental Nephrology</i> , <b>1993</b> , 1, 120-7		3
202	Nitric oxide synthesis and L-arginine in uremia. <i>Mineral and Electrolyte Metabolism</i> , <b>1997</b> , 23, 151-6		3
201	Angiotensin-converting enzyme inhibition prevents loss of glomerular hydraulic permeability in passive heyman nephritis. <i>Laboratory Investigation</i> , <b>1999</b> , 79, 1501-10	5.7	4
200	How much must blood pressure be reduced in order to obtain the remission of chronic renal disease?. <i>Journal of Nephrology</i> , <b>2000</b> , 13, 228-31	4.6	3
199	Renal cyclophilin-like protein gene expression parallels changes in sodium excretion in experimental nephrosis and is positively modulated by atrial natriuretic peptide. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1993</b> , 3, 1710-6	12.3	2
198	The kidney triggers graft-versus-host disease in experimental combined transplantation of kidney and stem cell-enriched peripheral leukocytes. <i>Journal of the American Society of Nephrology: JASN</i> , <b>1996</b> , 7, 2254-8	12.3	3
197	The Lancet Kidney Campaign: an opportunity for partnerships. <i>Lancet, The</i> , <b>2016</b> , 387, 1038-1039	36.2	2
196	Association of CFHR1 homozygous deletion with acute myelogenous leukemia in the European population. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 1234-7	1.8	2
195	The Glomerulus: Mechanisms and Patterns of Injury <b>2018</b> , 189-206		2
194	Acute Kidney Injury and Hemolytic Anemia Secondary to Mycoplasma pneumoniae Infection. <i>Nephron</i> , <b>2017</b> , 137, 148-154	3.1	2
193	Clinical trials: ISN-ACCTS: global initiatives to improve clinical research. <i>Nature Reviews Nephrology</i> , <b>2014</b> , 10, 426-7	14.3	2
192	Stamina therapies: Time to call a halt. <i>Nature</i> , <b>2014</b> , 506, 434	47.5	2
191	Optimizing allocation of kidneys from older donors. <i>American Journal of Transplantation</i> , <b>2011</b> , 11, 182; author reply 183	8.4	2
190	LITERATURE Watch Implications for transplantation. <i>American Journal of Transplantation</i> , <b>2013</b> , 13, 1625-1625		2
189	Introduction to Focus on Fabry nephropathy: biomarkers, progression, and disease severity. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2010</b> , 5, 359	6.7	2
188	Conversion from Brand-Name Neoral to the Generic Ciqorin in Stable Renal Transplant Recipients. <i>Nephron</i> , <b>2017</b> , 135, 173-180	3.1	2



187	Comparison of exposure response relationship of atrasentan between North American and Asian populations. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 545-552	6.5	2
186	Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation. <i>Nephron</i> , <b>2020</b> , 144, 195-203	3.1	2
185	Characterization of a Rat Model of Myeloperoxidase-Anti-Neutrophil Cytoplasmic Antibody-Associated Crescentic Glomerulonephritis. <i>Nephron</i> , <b>2021</b> , 145, 428-444	3.1	2
184	Albuminuria as a risk factor for mild cognitive impairment and dementia-what is the evidence?. <i>Nephrology Dialysis Transplantation</i> , <b>2021</b> ,	4.1	2
183	Preventing microalbuminuria with benazepril, valsartan, and benazepril-valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study. <i>PLoS Medicine</i> , <b>2021</b> , 18, e1003691	11.3	2
182	Mesenchymal Stromal Cell Therapy in Solid Organ Transplantation. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 618243	8.2	2
181	Low mortality and key aspects of delivery of care for end-stage renal disease in Italy. <i>Scientific World Journal, The</i> , <b>2009</b> , 9, 349-59	2.1	2
180	Genes and molecular medicine in the future of organ transplantation. <i>Current Opinion in Organ Transplantation</i> , <b>1999</b> , 4, 65	2.4	2
179	Angiotensin-converting enzyme 2: from a vasoactive peptide to the gatekeeper of a global pandemic. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2021</b> , 30, 252-263	3.4	2
178	Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade. <i>Expert Opinion on Pharmacotherapy</i> , <b>2005</b> , 6, 1931-42	3.9	2
177	What blood-pressure level provides greatest renoprotection in patients with diabetic nephropathy and hypertension?. <i>Nature Clinical Practice Nephrology</i> , <b>2006</b> , 2, 250-1		2
176	Antihypertensive therapy in chronic renal disease: a place for sympatholytic agents?. <i>Journal of Hypertension</i> , <b>2003</b> , 21, 1625-6	1.5	2
175	Angiotensin-converting enzyme inhibition or angiotensin receptor blockade in hypertensive diabetics?. <i>Current Hypertension Reports</i> , <b>2003</b> , 5, 364-7	4.5	2
174	Deficiency of ADAMTS-13 in thrombotic and thrombocytopenic purpura. <i>Journal of Thrombosis and Haemostasis</i> , <b>2003</b> , 1, 2040-2041	15	2
173	Thrombotic microangiopathies in the intensive care unit: many questions, some answers. <i>Contributions To Nephrology</i> , <b>2001</b> , 132, 53-67	1.5	2
172	Nitric oxide and renal perfusion in humans. <i>Journal of Hypertension</i> , <b>2002</b> , 20, 391-3	1.5	2
171	Effect of a novel immunosuppressant, ST1959, on the immune system and renal allograft survival in rats. <i>Transplantation</i> , <b>2005</b> , 80, 231-6	1.5	2
170	Prostacyclin and Thromboxane and the Development of Preeclampsia. <i>JAMA - Journal of the American Medical Association</i> , <b>2000</b> , 283, 1568	26.8	2

169	Transplant tolerance: facts and future. <i>Transplantation Proceedings</i> , <b>1999</b> , 31, 2955-7	1.1	2
168	Dearing--a report to be embraced. <i>Lancet, The</i> , <b>1997</b> , 350, 308	36.2	2
167	Innovative strategies for pharmacological intervention in immune damage to the kidney. <i>Nephrology Dialysis Transplantation</i> , <b>1995</b> , 10, 1131-1136	4.1	2
166	Clinical problem solving. The girl with the curl. <i>New England Journal of Medicine</i> , <b>1995</b> , 333, 928-31	57.2	2
165	Dissociation between antiproteinuric and antihypertensive effect of angiotensin converting enzyme inhibitors in rats. <i>American Journal of Physiology - Renal Physiology</i> , <b>1994</b> , 267, F1034-44	4.1	2
164	Glomerulonephritis. <i>Current Opinion in Nephrology and Hypertension</i> , <b>1995</b> , 4, 374	3.4	2
163	Platelets from Uraemic Patients React Normally to Prostacyclin. <i>International Journal of Artificial Organs</i> , <b>1980</b> , 3, 125-125	1.8	2
162	Mechanisms of progression of chronic renal disease. <i>Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia</i> , <b>2002</b> , 13, 250-6	0.6	2
161	SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet Aggregation.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 827146	8.2	2
160	Increased urinary excretion of endothelin-1 and its precursor, Big-endothelin-1, in rats chronically treated with cyclosporine. <i>Transplantation</i> , <b>1991</b> , 52, 175-7	1.5	2
159	Non-Shiga toxin-associated hemolytic uremic syndrome <b>2006</b> , 65-83		2
158	Heparin for hemodialysis: practical guidelines for administration and monitoring. <i>International Journal of Artificial Organs</i> , <b>1984</b> , 7, 269-74	1.8	2
157	A HOME-TREATMENT ALGORITHM BASED ON ANTI-INFLAMMATORY DRUGS TO PREVENT HOSPITALIZATION OF PATIENTS WITH EARLY COVID-19: A MATCHED-COHORT STUDY (COVER 2)		2
156	Excess total mortality during the Covid-19 pandemic in Italy: updated estimates indicate persistent excess in recent months.. <i>Medicina Del Lavoro</i> , <b>2022</b> , 113, e2022021	1.8	2
155	Italy, the Land of Holy Miracles--revisited. <i>Lancet, The</i> , <b>2016</b> , 387, 11-2	36.2	1
154	Hemolytic Uremic Syndrome in an Infant with Primary Hyperoxaluria Type II: An Unreported Clinical Association. <i>Nephron</i> , <b>2019</b> , 142, 264-270	3.1	1
153	Bleeding and Hemostasis in Acute Renal Failure <b>2019</b> , 630-635.e2		1
152	Interplay between Diagnostic Criteria and Prognostic Accuracy in Chronic Kidney Disease. <i>PLoS Medicine</i> , <b>2016</b> , 13, e1002129	11.3	1

151	ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—the Berlin Roadmap. <i>Kidney International Reports</i> , <b>2016</b> , 1, 327-339	0.9	1
150	Kidney Transplantation, Bioengineering, and Regeneration <b>2017</b> , xxv		1
149	SaO006INCREASED PRE-GLOMERULAR RESISTANCE AND KIDNEY HYPOPERFUSION MAY SUSTAIN ACCELERATED GFR DECLINE IN HYPERTENSIVE, TYPE 2 DIABETICS WITH NORMAL AND HIGH NORMAL ALBUMINURIA. <i>Nephrology Dialysis Transplantation</i> , <b>2018</b> , 33, i317-i317	4.1	2
148	A comparison of metrics and performance characteristics of different search strategies for article retrieval for a systematic review of the global epidemiology of kidney and urinary diseases. <i>BMC Medical Research Methodology</i> , <b>2018</b> , 18, 110	4.6	1
147	Dreaming of normoglycaemia with fewer diet restrictions. <i>Lancet Diabetes and Endocrinology</i> , <b>2014</b> , 2, 350-1	17.4	1
146	West Meets East. <i>Kidney Diseases (Basel, Switzerland)</i> , <b>2015</b> , 1, 4-7	3.2	1
145	In patients with atypical hemolytic uremic syndrome C5 activation causes loss of endothelial thromboresistance. <i>Molecular Immunology</i> , <b>2011</b> , 48, 1680	4.2	1
144	Exciting times for renal medicine. <i>Lancet, The</i> , <b>2010</b> , 375, 1227-8	36.2	1
143	Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin-angiotensin-aldosterone system blockade in albuminuric hypertensive type 2 diabetes mellitus patients. <i>Journal of Hypertension</i> , <b>2011</b> , 29, 2031-7	1.5	1
142	Role of Proteinuria in Progression <b>2008</b> , 2563-2576		1
141	Functional Magnetic Resonance Imaging Versus Kidney Biopsy to Assess Response to Therapy in Nephrotic Syndrome: A Case Report. <i>Kidney Medicine</i> , <b>2020</b> , 2, 804-809	2.7	1
140	Preimplantation Histological Score Associates with 6-Month GFR in Recipients of Perfused, Older Kidney Grafts: Results from a Pilot Study. <i>Nephron</i> , <b>2021</b> , 145, 137-149	3.1	1
139	and Copy Number Variations in C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis. <i>Frontiers in Genetics</i> , <b>2021</b> , 12, 670727	4.4	1
138	Human iPSC-derived neural crest stem cells can produce EPO and induce erythropoiesis in anemic mice. <i>Stem Cell Research</i> , <b>2021</b> , 55, 102476	1.5	1
137	SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Thrombus Formation. <i>SSRN Electronic Journal</i> ,	1	1
136	A Simple, Home-Therapy Algorithm to Prevent Hospitalization for COVID-19 Patients: A Retrospective Observational Matched-Cohort Study		1
135	Pathophysiology of Chronic Kidney Disease <b>2009</b> , 422-435		1
134	Medicine and art: one culture?. <i>Kidney International</i> , <b>2009</b> , 75, 347-8	9.6	1

133	The Onset and Resolution of Renal Fibrosis: A Human Perspective <b>2016</b> , 351-366		1
132	Treatment of Anemia and Bleeding in Chronic Kidney Disease <b>2008</b> , 756-764		1
131	How should patients with, or at risk of, cardiovascular disease be screened for chronic kidney disease?. <i>Nature Clinical Practice Nephrology</i> , <b>2007</b> , 3, 126-7		1
130	Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome <b>2003</b> ,		1
129	Renin-angiotensin system, proteinuria, and tubulointerstitial damage. <i>Contributions To Nephrology</i> , <b>2001</b> , 135, 187-99	1.5	1
128	Gene therapy to the kidney. <i>Contributions To Nephrology</i> , <b>2001</b> , 136, 140-56	1.5	1
127	Pharmacogenetics and pharmacogenomics of immunosuppressive agents: perspective for individualized therapy. <i>Personalized Medicine</i> , <b>2004</b> , 1, 53-62	2.1	1
126	Kidney prevention recipes for your office practice. <i>Kidney International</i> , <b>2005</b> , S136-41	9.6	2
125	Pharmacokinetics and renal function after conversion from standard to microemulsion formulation of cyclosporine in stable renal transplant patients. <i>Transplantation Proceedings</i> , <b>1998</b> , 30, 1654-5	1.1	1
124	Optimization of cyclosporine therapy in kidney transplantation. <i>Transplantation Proceedings</i> , <b>1998</b> , 30, 1673-6	1.1	1
123	Reduced fibrinolytic activity in glomeruli isolated from rabbits infused with tumor necrosis factor. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , <b>1993</b> , 23, 173-8		1
122	Defective glomerular [3H]lysoPAF metabolism in the autologous phase of rabbit nephrotoxic nephritis. <i>Kidney International</i> , <b>1993</b> , 44, 747-54	9.6	1
121	Are "routine" clinical and laboratory examinations of any help in the treatment of chronic hemodialysis patients?. <i>American Journal of Kidney Diseases</i> , <b>1987</b> , 10, 23-7	7.2	1
120	Aspirin and thrombosis in patients undergoing hemodialysis. <i>New England Journal of Medicine</i> , <b>1980</b> , 302, 1420-1	57.2	1
119	Severe glomerular epithelial cell damage does not prevent passive Heyman nephritis in rats. <i>Clinical and Experimental Immunology</i> , <b>1983</b> , 51, 38-44	5.9	1
118	Imaging the Kidney with an Unconventional Scanning Electron Microscopy Technique: Analysis of the Subpodocyte Space in Diabetic Mice.. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23,	6.1	1
117	Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment. <i>Nephrology Dialysis Transplantation</i> , <b>2021</b> ,	4.1	1
116	Prevention of Chronic Renal Diseases in the Elderly <b>2008</b> , 231-255		1

115	Thrombotic Microangiopathy <b>1998</b> , 513-527		1
114	Cyclosporine/tacrolimus (FK-506) <b>1998</b> , 275-300		1
113	Innovative strategies for pharmacological intervention in immune damage to the kidney. <i>Nephrology Dialysis Transplantation</i> , <b>1995</b> , 10, 1131-6	4.1	1
112	Xenotransplantation: a challenge for the future of transplant medicine. <i>Swiss Medical Weekly</i> , <b>1998</b> , 128, 952-60	2.8	1
111	Abdominal pain and acute nephritis in a man with a recent renal transplant. <i>Journal of Nephrology</i> , <b>1998</b> , 11, 196-8	4.6	1
110	Treatment of adult hemolytic-uremic syndrome. <i>Advances in Nephrology From the Necker Hospital</i> , <b>2000</b> , 30, 83-94		1
109	Molecular basis of familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. <i>Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia</i> , <b>2003</b> , 14, 342-50	0.6	1
108	A RECURRENT QUESTION FROM A PRIMARY CARE PHYSICIAN: HOW SHOULD I TREAT MY COVID-19 PATIENTS AT HOME?		1
107	Why rare diseases?. <i>Annali Dell'istituto Superiore Di Sanita</i> , <b>2011</b> , 47, 94-7	1.5	1
106	Nephropathy in NIDDM Patients, Predictors of Outcome <b>2000</b> , 237-246		1
105	Kidney Disease <b>2017</b> , 235-252		1
104	Increased Fragmentation of von Willebrand Factor, Due to Abnormal Cleavage of the Subunit, Parallels Disease Activity in Recurrent Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura and Discloses Predisposition in Families. <i>Blood</i> , <b>1999</b> , 94, 610-620	2.1	1
103	A Home-Treatment Algorithm Based on Anti-inflammatory Drugs to Prevent Hospitalization of Patients With Early COVID-19: A Matched-Cohort Study (COVER 2).. <i>Frontiers in Medicine</i> , <b>2022</b> , 9, 785785	4.7	1
102	Bone Marrow Mesenchymal Stem Cells in Organ Repair and Strategies to Optimize their Efficacy <b>2011</b> , 299-312		1
101	Initial combination therapy for treatment of hypertension. <i>Lancet, The</i> , <b>2011</b> , 377, 1491; author reply 1492	36.2	
100	ERA-EDTA Immunonephrology working group. <i>Nephrology Dialysis Transplantation</i> , <b>2010</b> , 25, 1706-7	4.1	0
99	Amnion epithelial cells are an effective source of factor H and prevent kidney complement deposition in factor H-deficient mice. <i>Stem Cell Research and Therapy</i> , <b>2021</b> , 12, 332	8	0
98	Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 711915	8.2	0

97	Ramipril and Cardiovascular Outcomes in Patients on Maintenance Hemodialysis: The ARCADIA Multicenter Randomized Controlled Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2021</b> , 16, 575-587	6.7	1
96	New strategies to prevent cardiovascular risk in chronic kidney disease. <i>Kidney International</i> , <b>2008</b> , S1	9.6	0
95	Clinical perspectives in the prevention and treatment of chronic nephropathy, including an overview of the DEMAND Study. <i>Clinical Therapeutics</i> , <b>2007</b> , 29, S64-S72	3.4	0
94	Long-term kidney and systemic effects of calorie restriction in overweight or obese type 2 diabetic patients (C.Re.S.O. 2 randomized controlled trial).. <i>Diabetes Research and Clinical Practice</i> , <b>2022</b> , 185, 109804	7.2	0
93	Post-translational modifications by SIRT3 de-2-hydroxyisobutyrylase activity regulate glycolysis and enable nephrogenesis. <i>Scientific Reports</i> , <b>2021</b> , 11, 23580	4.7	0
92	Fresh lemon juice supplementation for the prevention of recurrent stones in calcium oxalate nephrolithiasis: A pragmatic, prospective, randomised, open, blinded endpoint trial.. <i>EClinicalMedicine</i> , <b>2022</b> , 43, 101227	11	0
91	Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes.. <i>EClinicalMedicine</i> , <b>2022</b> , 43, 101240	11	1
90	Glomerular resistances predict long-term GFR decline in type 2 diabetic patients without overt nephropathy: a longitudinal subgroup analysis of the DEMAND trial. <i>Acta Diabetologica</i> , <b>2021</b> , 59, 309	3.8	0
89	Proteinuria and Tubulotoxicity <b>2019</b> , 197-214		0
88	Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.. <i>JAMA - Journal of the American Medical Association</i> , <b>2022</b> , 327, 1888-1898	26.8	0
87	Shiga Toxin 2 Triggers C3a-Dependent Glomerular and Tubular Injury through Mitochondrial Dysfunction in Hemolytic Uremic Syndrome. <i>Cells</i> , <b>2022</b> , 11, 1755	7.6	
86	The Glomerulus: Mechanisms and Patterns of Injury <b>2014</b> ,		0
85	Developmental Approaches to Kidney Regeneration <b>2017</b> , 1039-1050		
84	Prevention and Therapeutic Management of Bleeding in Dialysis Patients <b>2017</b> , 334-345.e1		
83	Maintenance Immunosuppression in Kidney Transplantation <b>2017</b> , 259-276		
82	Pharmacotherapy options for membranous nephropathy. <i>Expert Opinion on Orphan Drugs</i> , <b>2016</b> , 4, 185-196		
81	Orphan drugs - Authors' reply. <i>Lancet, The</i> , <b>2019</b> , 393, 1595-1596	36.2	
80	Hemolytic Uremic Syndrome <b>2019</b> , 294-301.e2		

79	Mesenchymal stromal cell-based therapy in kidney diseases and transplantation. <i>Italian Journal of Medicine</i> , <b>2019</b> , 13, 3-14	0.4
78	Why and how did Leonardo happen: the Renaissance context. <i>Lancet, The</i> , <b>2019</b> , 393, 1396-1397	36.2
77	Kidney transplantation from a donor with acute kidney injury: an unexpected outcome. <i>American Journal of Transplantation</i> , <b>2014</b> , 14, 977-8	8.4
76	Role of Proteinuria in the Progression of Renal Disease <b>2013</b> , 2961-2983	
75	Reply: Nephrons are generated via a series of committed progenitors. <i>Nature Reviews Nephrology</i> , <b>2014</b> , 10, 491	14.3
74	Cells for treating organ damage: how long will we need them?. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2011</b> , 22, 590-2	12.3
73	ACP Journal Club. Prednisolone plus chlorambucil preserved renal function in membranous nephropathy. <i>Annals of Internal Medicine</i> , <b>2013</b> , 158, JC9	7.8
72	Current Status of Islet Transplantation <b>2014</b> , 583-598	
71	Cavour's death and the political difficulties of Italian medicine [Author's reply. <i>Lancet, The</i> , <b>2012</b> , 380, 108-109	36.2
70	Thrombotic microangiopathies <b>2012</b> , 278-282	
69	The Glomerulus: Mechanisms of Injury* <b>2010</b> , 245-261	
68	Prevention and Therapeutic Management of Bleeding in Dialysis Patients <b>2008</b> , 445-456	
67	Protective Effects of Human Nonrenal and Renal Stromal Cells and Their Conditioned Media in a Rat Model of Chronic Kidney Disease. <i>Cell Transplantation</i> , <b>2020</b> , 29, 963689720965467	3.8
66	Tissue Engineering of Renal Tissue (Kidney) <b>2017</b> , 575-602	
65	AAV9-mediated engineering of autotransplanted kidney of non-human primates. <i>Gene Therapy</i> , <b>2017</b> , 24, 308-313	3.8
64	The Vatican-Mario Negri-Lancet Commission on the value of life. <i>Lancet, The</i> , <b>2017</b> , 390, 1573	36.2
63	Addressing acute kidney injury in critically ill newborn babies. <i>The Lancet Child and Adolescent Health</i> , <b>2017</b> , 1, 161-163	13.7
62	Nephrology Worldwide [A Book Review. <i>Nephron</i> , <b>2021</b> , 145, 212-213	3.1

- 61 Insights into Glomerular Filtration and Albuminuria. *New England Journal of Medicine*, **2021**, 385, 477 57.2
- 60 Rare but Relevant Kidney Disorders Seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance (SeSAME syndrome) caused by mutations in KCNJ10. *Proc Natl Acad Sci U S A* 106: 5842-5847, 2009 Epilepsy, ataxia, sensorineural deafness, tubulopathy, and KCNJ10 6.7
- 59 Effects of Combined Ezetimibe and Simvastatin Therapy as Compared With Simvastatin Alone in Patients With Type 2 Diabetes: A Prospective Randomized Double-Blind Clinical Trial: Response to Sarigianni, Katsiki, and Mikhailidis. *Diabetes Care*, **2010**, 33, e133-e133 14.1
- 58 A mouse model of non-Shiga toxin-associated haemolytic uraemic syndrome. *Nephrology Dialysis Transplantation*, **2008**, 23, 462-5 4.1
- 57 Chapter 14 Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. *Handbook of Systemic Autoimmune Diseases*, **2007**, 257-282 0.3
- 56 Target haemoglobin concentrations in chronic kidney disease. *Lancet, The*, **2007**, 369, 1515 36.2
- 55 Minimisation of immunosuppression in transplantation [Authors' reply]. *Lancet, The*, **2007**, 370, 654 36.2
- 54 Corrigendum to [et al] assume that hepatitis C reduces the cardiovascular risk in dialysis patients: Are there practical implications? [J Hepatol 44 (2006) 837-838]. *Journal of Hepatology*, **2006**, 45, 339 3.1
- 53 Angiotensin-receptor blockers for renal protection in Type 2 diabetes. *Aging Health*, **2006**, 2, 295-301
- 52 Is mycophenolate mofetil better than azathioprine in organ transplantation?. *Transplantation*, **2006**, 82, 1242-3 1.5
- 51 The uses of error: diagnostic preferences. *Lancet, The*, **2001**, 358, 1005 36.2
- 50 The scientific care for prevention: an overview. *Kidney International*, **2005**, S8-13 9.6
- 49 Nephrology. Reducing mortality and increasing awareness. *Lancet, The*, **1998**, 352 Suppl 4, SIV20 36.2
- 48 Double transplant of marginal kidneys. *Transplantation Proceedings*, **1999**, 31, 2962-4 1.1
- 47 Hemostasis in renal failure Hämostasie bei Nierenversagen. *Intensivmedizin Und Notfallmedizin*, **1998**, 35, 382-389
- 46 Haemolytic-Uraemic Syndrome and Thrombotic Thrombocytopenic Purpura. *Vascular Medicine Review*, **1993**, vmr-4, 273-292
- 45 Kidney/pancreas transplantation. *Lancet, The*, **1994**, 343, 971-2 36.2
- 44 Analysis by fast atom bombardment mass spectrometry of phospholipids from tubuli, glomeruli, and urine of normal rats and rats with acute renal failure. *Biochemical Medicine and Metabolic Biology*, **1992**, 48, 219-26



- 43 Induction of unresponsiveness via intrathymic inoculation. *Lancet, The*, **1991**, 337, 1487-8 36.2
- 42 Effect of ticlopidine on the evolution of renal disease in rats with reduced renal mass. *Contributions To Nephrology*, **1990**, 81, 279-88 1.5
- 41 Haemolytic Uraemic Syndromes **1984**, 276-297
- 40 Vascular prostacyclin and plasminogen activator activity in experimental and clinical conditions of disturbed haemostasis or thrombosis. *Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research*, **1979**, 8, 300-11
- 39 Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19.. *Frontiers in Pharmacology*, **2022**, 13, 842473 5.4
- 38 Induction of Tolerance in Allograft Transplantation **2007**, 461-474
- 37 Thrombogenesis and Anticoagulation in Patients Undergoing Chronic Hemodialysis **1996**, 323-332
- 36 Interstitial Nephritis **2006**, 636-642
- 35 Two-hour post-dose cyclosporine monitoring does not fit all in kidney transplantation. *Therapy: Open Access in Clinical Medicine*, **2005**, 2, 95-105
- 34 Possible role of HLA-B8 antigen as a genetic marker of autoimmune thrombocytopenia in a patient with myasthenia gravis. *Thrombosis and Haemostasis*, **1977**, 38, 593-4 6.8
- 33 ADP, ristocetin, bovine factor VII and thrombasthenic platelets. *Thrombosis and Haemostasis*, **1976**, 36, 286-8 6.8
- 32 Prostacyclin and hemolytic uremic syndrome: from the laboratory to an international registry. *International Journal of Artificial Organs*, **1987**, 10, 337-40 1.8
- 31 Platelets from uraemic patients react normally to prostacyclin. *International Journal of Artificial Organs*, **1980**, 3, 125 1.8
- 30 Glomerulonephritis: from new knowledge on the mechanisms of tissue damage to novel therapies. *Current Opinion in Nephrology and Hypertension*, **1995**, 4, 374-82 3.4
- 29 Renal transplant tolerance: molecular mechanisms of T cell regulation. Introduction. *Experimental Nephrology*, **1993**, 1, 69-71
- 28 Intrathymic transplantation of donor cells allows a stabilized, incompatible renal transplant to survive indefinitely after cyclosporine withdrawal. *Experimental Nephrology*, **1993**, 1, 185-9
- 27 Endothelin and renal disease progression. *Experimental Nephrology*, **1994**, 2, 133
- 26 Platelet and Vascular Prostaglandins in Uremia and Thrombotic Microangiopathy **1983**, 319-325

- 25 Platelet Prostaglandin Production in the Nephrotic Syndrome **1983**, 327-331
- 24 Molecular Medicine in Organ Transplantation: How and When? **2001**, 317-334
- 23 Pharmacologic Monitoring of Immunosuppressive Drugs **2001**, 43-59
- 22 Platelets and renal diseases **2002**, 837-851
- 21 Commenti alla delibera. *Mecosan*, **2017**, 173-180 0.1
- 20 Acute Renal Failure in Kidney Transplant Recipients **2019**, 1279-1285.e3
- 19 Successes and Disappointments with Clinical Islet Transplantation **2015**, 1245-1274
- 18 Reply: Nephrons are generated via a series of committed progenitors. *Nature Reviews Nephrology*, 14.3
- 17 Mesenchymal Stem Cells and Their Use in Acute Renal Injury **2009**, 216-220
- 16 Bleeding and Hemostasis in Acute Renal Failure **2009**, 385-390
- 15 Hemolytic Uremic Syndrome **2009**, 373-378
- 14 Acute Renal Failure in Kidney Transplant Recipients **2009**, 1660-1665
- 13 Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura **2010**, 349-364
- 12 Nondiabetic Kidney Disease **2010**, 341-356
- 11 Successes and Disappointments with Clinical Islet Transplantation **2013**, 1-27
- 10 Lupus Nephritis 244-252
- 9 Prostacyclin and thromboxane and the development of preeclampsia. *JAMA - Journal of the American Medical Association*, **2000**, 283, 1568; author reply 1568-9 26.8
- 8 Platelet and Vascular Prostaglandins in Uraemia, Thrombotic Microangiopathy and Pre-Eclampsia **1982**, 209-215

- 7 Prostanoid-Related Platelet Abnormalities in Renal Disease **1984**, 1406-1411
- 6 Eicosanoids and Acute Renal Failure. *Current Concepts in Critical Care*, **1990**, 115-129
- 5 Models of human renal disease **1990**, 111-123
- 4 Mechanisms and Mediators of Cyclosporine-Induced Renal Vascular Changes **1991**, 543-554
- 3 Altered Renovascular Endothelial Functions During Nephrotoxicity **1991**, 157-166
- 2 Aspirin in Hypertension of Pregnancy **1992**, 93-105
- 1 A Putative Role of NO and Oxidant Injury in the Pathogenesis of Hemolytic Uremic Syndrome **1997**, 418-427